D3.3 Update of potential data sources with RWE data in Europe

116020 - ROADMAP

Real world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform

WP3 – WP Identification, mapping and integration of RWE

Lead contributors	Stephanie Vos
	Olin Janssen
Other contributors	Pieter Jelle Visser
	Antje Hottgenroth
	Lars Pedersen
	Anna Ponjoan
	Christoph Jindra
	Kirsi Kinnunen
	Iain Simpson

Due date	30/04/2018
Delivery date	15/10/2018
Deliverable type	R
Dissemination level	PU

Description of Work	Version	Date
	V2.0	08/11/2017

Table of contents

Document History

Version	Date	Description
V1.0	29/09/2018	Draft for Consortium review
V2.0	01/10/2018	Format editing by Glòria Garcia (SYNAPSE)
V3.0	05/10/2018	Consortium review
V4.0	15/10/2018	Final Version

1. Introduction

The identification and characterisation of the data sources in order to create a landscape of available real world health care data is the first step to providing an understanding of currently available data for the relevant outcomes and outlining potential gaps in currently available information about Alzheimer's disease at various stages. Since the landscape of data should be sustainable information that is available for the current ROADMAP objectives as well as future research on the various stages of Alzheimer's disease, it should be documented in an accessible data source catalogue with curation and search features. For that purpose, the existing EMIF AD, DPUK and EMIF EHR catalogues were selected as the preferred repositories, (https://emif-catalogue.eu, https://dementiasplatform.uk), but at the same time taking into account the different fingerprinting needs for cohort type and EHR/national register type data (see figure 1).



Figure 1. The Data Pyramid – EMIF catalogue selection

All three catalogues provide data characterization items, which are already designed for fingerprinting Dementia/Alzheimer's disease related characteristics and were further adjusted by adding characteristics as identified in ROADMAP work packages. Additional fingerprinting categories were added to the EMIF-AD Catalogue based on suggestions by representatives from each work package. As a result of this, questions on the availability of data on mortality, health resource utilization, remote monitoring technologies, and lifestyle have been incorporated in the fingerprinting questionnaire.

The overview of data sources was fed mainly by 5 knowledge resources:

- The ROADMAP consortium list of accessible data sources (FPP)
- The EMIF AD + EHR catalogue current fingerprinted data sources
- The DPUK catalogue of data sources
- The EU Dementia Mapping project results
- ROADMAP partner data source landscaping project

These resources were investigated in depth for this Final Overview of Potential Data Sources, as well as additional potential data sources suggested to be of interest by ROADMAP members. All data sources were fingerprinted in the EMIF-AD Catalogue.

2. Methods

The method used for Deliverable 3.1, which was to provide an Overview of potential data sources with RWE data in Europe, was mainly through interrogation of knowledge readily available to ROADMAP consortium members and similar mapping exercises. This method was continued and extended for the present Deliverable 3.3.

Knowledge Resources for the Final Overview incorporated in the Data Cube include:

- EMIF-AD + EHR catalogue
- DPUK catalogue
- EU dementia cohort mapping project
- Data source mapping project results provided by consortium members (Lilly)
- Networking of consortium members with the scientific community (Annex III)



Figure 2. Data Source Information Overview

Studies that were identified via mapping projects and networking of consortium members that were not yet included in the EMIF-AD Catalogue are continuously being fingerprinted for the Catalogue.

We prepared an overview of data collected in the different data sources. Characterization of the data sources in our overview was based on the 'Data Cube' that was developed within the ROADMAP project and described in detail in Deliverable 4.2. The Data Cube was developed to create a comprehensive overview of the available RWE data and allows combination of information on cohort data, clinical trial data and EHR data. The Data Cube is based on the WP2 outcomes that were identified to be of relevance to patients, caregivers and healthcare professionals and covers the following domains of outcomes:

- Source population (setting and design)
- Clinical diagnosis
- Disease severity and progression
- Cognitive abilities

- Functional ability and independence
- Behavioural and neuropsychiatric symptoms
- Medical investigations (biomarker assessments and physical and neurological examinations)
- Assessments by health care professional
- Use of healthcare and social services (patient-related and caregiver-related)
- Therapeutic treatment
- Significant disease-related life events (e.g. hospitalisation or institutionalisation)
- Patient quality of life
- Quality of the carer's and family's lives
- Mortality and comorbidity (In the Data Cube, mortality and comorbidities were part of the same outcome domain. For this overview, we decided to describe them separately since they are two different outcomes and differences exist in the amount of information collected in data sources for each of these two outcomes).

The above outcome domains were all listed in a user-friendly Excel file together with suboutcomes and measurements/scales of these outcomes (Link to data cube form). The presence or absence of all these outcomes was recorded for each data source from our Knowledge Resources. Thereafter the information of each data source was merged into a summary overview to identify data gaps in each outcome domain.

3. Results

3.1. Consolidation of Data Source Information from Knowledge Resources

Data sources identified through different Knowledge Resources were consolidated to identify overlap and to provide an initial list of unique sources of data. This identified 300 unique data sources in Europe, which are listed in Annex III.



Figure 3. Availability of outcomes across data sources

From these 300 unique data sources, the Data Cube form was completed for 71 sources. These sources included 4 Clinical Trial Placebo data sources, 4 Electronic Health Registries, and 63 cohort studies. From the 63 cohort studies, 41 were included in the EMIF-AD Catalogue, 20 were included in the DPUK Catalogue, and 2 cohort studies' Data Cube forms were completed by consortium data owners (Figure 3A & 3B).

3.1.1. Identification of gaps

To identify gaps across the main outcomes in data sources, we analysed the percentage of data sources included in the Data Cube with information on at least one of the suboutcomes within each outcome category, as described below. Both direct and indirect availability in each source was taken into account.

Disease severity and progression

The domain disease severity and progression included questions on the staging of dementia severity and whether an observation of global improvement, stability or decline was assessed.

63% of all sources collected information on disease severity and progression. When only looking at the Clinical Trial Placebo data sources, all sources had collected some information on disease severity and progression, while for the EHR sources this was covered in 75% of the sources, and for cohort studies 58% collected information on disease severity and progression.

Cognitive abilities

The domain cognitive abilities included measures of cognition, such as memory functioning, language and attention/executive functioning.

Most data sources had data available on cognitive abilities (89%). All 4 Clinical Trial Placebo data collected some information on cognitive abilities, while none of the EHR sources had this information available. 95% of all cohort sources had information available on cognitive abilities.

Functional ability and independence

Information on functional ability and independence was collected regarding basic activities of daily living and instrumental activities of daily living, as well as a clinical judgement on the degree of dependence and a measure of social engagement.

73% of all sources collected information on functional ability and independence. For the Clinical Trial Placebo data, all 4 sources collected at least some information on functional ability and independence. For the EHR sources, functional ability and independence was collected in 3 of the 4 sources and for cohort studies it was collected in 70% of all 63 sources.

Behavioural and Neuropsychiatric Symptoms

The domain behavioural and neuropsychiatric symptoms included assessments of various behavioural and neuropsychiatric symptoms known to be commonly associated with Alzheimer's disease dementia. Examples of these symptoms are sleep disturbance, aggression, apathy, depression and anxiety.

Behavioural and neuropsychiatric symptoms were measured in 92% of all sources. All 4 Clinical Trial Placebo data sources and all 4 EHR sources collected some information on this domain, and 91% of the cohort studies collected at least some information on behavioural and neuropsychiatric symptoms.

Medical investigations

APOE-e4 genotype

Information on APOE-e4 genotype was collected in 51% of all sources. While all 4 Clinical Trial Placebo data sources collected this, none of the EHR sources had information available on APOE-e4 genotype, and 44% of all cohort studies had APOE-e4 genotyping available.

Amyloid and tau biomarkers

Amyloid and tau biomarker measures were available in 56% of all data sources. These measures were collected in all 4 Clinical Trial Placebo data sources, and in 1 of 4 EHR sources. For the cohorts, 51% of the sources collected amyloid and tau biomarker measures.

Functional and structural neuroimaging biomarkers

Functional neuroimaging biomarkers were collected in 21% of all data sources. All 4 Clinical Trial Placebo sources, none of the EHR sources, and 11% of the cohort sources collected information on functional neuroimaging.

Structural neuroimaging biomarkers were collcted in 47% of all data sources. Again, all 4 Clinical Trial Placebo sources and none of the EHR sources collected these. For the cohorts, structural neuroimaging biomarkers were included in 40% of all studies.

Physical and neurological examination

Physical and neurological examination information was collected in 77% and 49% of all studies, respectively. All 4 Clinical Trial Placebo data sources collected these, and none of the 4 EHR sources. For cohort sources, physical examination information was collected in 75% of the sources and neurological examination information was collected in 43% of the sources.

Assessments by healthcare professional

The assessment by healthcare professionals category included questions on the data and frequency of healthcare appointments, and questions on the data and frequency that tests were adminstered. Assessments by healthcare professionals were included in 42% of all sources. All Clinical Trial Placebo data sources included these, and 75% of the EHR sources. 35% of cohort studies included assessments by healthcare professionals.

Use of healthcare and social services

Information on the use of healthcare and social services for both the patient and caregivers was collected through assessments of for example living accommodation, healthcare resource utilization and both formal and informal caregiving time.

Patient use of healthcare and social services was assessed in 68% of all data sources. All Clinical Trial Placebo data sources and all EHR sources included these assessments, versus 63% of cohort studies.

Use of healthcare and social services by caregivers was collected in only 15% of all sources. All Clinical Trial Placebo data sources collected this information, while none of the EHR sources and 5% of cohort sources collected information on healthcare and social service use by caregivers.

Therapeutic treatment

The domain therapeutic treatment included questions regarding use of both dementia-specific medication and other medications. Furthermore, questions regarding side effects, medical device use and other therapeutic interventions were included.

85% of all sources assessed information regarding therapeutic treatment. All Clinical Trial Placebo and EHR sources included this information, and 83% of all cohort studies assessed therapeutic treatment.

Significant disease-related life events

Significant disease-related life events assessed in this domain included ability to drive, hospitalization, institutionalization, need for assistance at home, need for full time care and safety, among other life-events.

Information on significant disease-related life events was collected in 53% of all sources. All Clinical Trial Placebo and EHR sources collected this, versus 48% of cohort studies.

Quality of life

Quality of life was assessed as, for example, self-reported patient QoL, proxy-reported patient QoL, caregiver QoL, and caregiver-perceived burden.

Patient quality of life was assessed in 42% of the data sources. All 4 Clinical Trial Placebo data sources collected information on patient quality of life, versus 2 of 4 EHR sources. For the cohort studies, patient quality of life was assessed in 35% of studies.

Information on quality of the carer's and family's lives was collected in 13% of all studies. It was collected in none of the 4 Clinical Trial Placebo data sources and in 2 of 4 EHR sources. 11% of the cohort sources collected information on quality of life for the patient's carer and family.

Mortality

Mortality was registered in 61% of all data sources. All 4 Clinical Trial Placebo data sources and all 4 EHR sources collected information on mortality, versus 56% of the cohort sources.

Comorbidities

Information on comorbidities was collected in 94% of all data sources. All Clinical Trial Placebo data sources and EHR sources covered this, versus 94% of cohort sources.

3.1.2. Conclusions

By combining information from different data sources (Clinical Trial Placebo data, EHR data and cohort data), we aimed to identify possible gaps in the collection of information on different outcome categories. In general, most of the different sources had at least some information available on the different outcomes.

When considering all three data source types, the outcomes that were collected in most of the data sources (>80%) were *Comorbidities*, *Cognitive abilities*, and *Therapeutic treatment*. The outcomes that were collected the fewest (<30%) were *Quality of the carer's and family's lives*, *Caregiver use of healthcare and social services*, and *Functional neuroimaging biomarkers*.

When considering only the four Clinical Trial Placebo data sources, information on all outcome domains was collected, except for *Quality of the carer's and family's lives*.

When considering only EHR data sources, the most collected (100%) outcome domains were *Comorbidities, Mortality, Significant disease-related life events, Therapeutic treatment, Use of healthcare and social services by patient*, and *Behavioural and Neuropsychiatric symptoms*. Outcome domains that were not collected in any of the EHR sources were *Cognitive abilities*, *APOE-e4 genotype*, *Functional and structural neuroimaging biomarkers*, *Physical and neurological examination*, and *Caregiver use of healthcare and social services*.

When considering only cohort data sources, outcome domains that were best collected (>75%) across the different cohort studies were *Cognitive abilities*, *Comorbidities*, T*herapeutic treatment and Physical examination*. Outcome domains that were collected the fewest (<25%) were *Quality of the carer's and family's lives, Caregiver use of healthcare and social services*, and *Functional neuroimaging biomarkers*.

Data sources differ in their suitability for answering specific research questions, and one should be aware of the limitations of each type of data source. In general, EHR data sources provide less detailed information and are less suitable for the investigation of etiological causes of dementia or predementia stages. Both EHR and cohort studies collected less information on caregiver outcomes and health resource utilization. Clinical Trial Placebo data covered most outcomes, which could be due to the fact that these studies are usually set up to cover also outcomes considered important by regulators and payers.

For this identification of gaps across different data sources, we investigated the availability of one or more outcomes per domain category. Maintaining stricter criteria (e.g. at least 3 sub-outcomes collected for each domain) could be of added value. WP 2 Deliverable 2.5 provides a more detailed gap analyse of the outcomes. Another limitation could be the potential confounding effect of different perspectives to complete the Data Cube forms across the different researchers.

Since the amount of Clinical Trial Placebo data sources and EHR sources was considerably smaller than the amount of cohort sources included in this overview, our conclusions should be treated with caution when considered in a broader perspective. Nevertheless, we believe that this overview reflects relatively well the availability of important outcomes in different data sources.

3.2. ROADMAP consortium accessible Data Sources

The ROADMAP consortium already has access to several of the identified data sources. The level of access governance to these data sources varies and there are 3 scenarios (see Figure 4):

- The ROADMAP consortium partner has direct governance over the data and is the sole/main decision maker to provide access.
- The ROADMAP consortium partner is part of the governance committee or has experience with the application process and will serve as the facilitator to request access to the data.
- ROADMAP has to follow the usual application process for access to the data – no ROADMAP partner will be the single point of contact for facilitation.



Figure 4. Consortium Data Source Access Map

A contact list for all data sources was created including high level information on expected timelines for access application and approval and is now integrated into the ROADMAP general contact list. It should be noted, that requests for data access have to be submitted with a study/project outline, and access governance processes of each individual data source have to be followed. We have received access to 24 data sources for analyses as part of ROADMAP Work Packages 4 and 5 (see Deliverable 3.4).

3.3. National Registries and EHR databases

National Registries, national claims and EHR databases are available through, or approached by, ROADMAP consortium members in several countries. Most of the national registers are well described and in the public domain and information was not transferred to the EMIF-EHR catalogue in these cases (e.g. various Swedish national registries). EHR database information has been added to the EMIF EHR catalogue and for disease-specific registries it was determined based on the general characteristics, whether a fingerprinting in the EHR or the AD catalogue was of most benefit.

Data sources available to ROADMAP are diverse and include information recorded in primary care, during admission to hospital, in ambulatory care, at specialized clinics, nursing homes and in other institutions responsible for care of AD patients. These data sources are a particular powerful resource for tracking AD related comorbidities and they often facilitates long term follow-up of patients in large cohorts defined by a geographical area, a catchment area or a database system like an EMR.

To obtain real-world evidence from these data sources, one has to be aware of the many pitfalls and the context in which these data are generated. In the following sections, we will briefly describe each

data system, their unique features and limitations. In addition, we will provide a few examples of their contributions to the research in the field of AD and related diseases.

Denmark

Denmark has a long tradition of using registries in research and some of the oldest disease registries are still in use today; including the Danish Cancer Registry established in 1943 and the Nationwide Psychiatric Registry dating back to the 1970s. The list of AD relevant data sources includes data from in-patient, outpatient and ER visits from all somatic hospitals in Denmark. Surgical procedures and selected in-hospital treatments are available since 1999. In addition, all prescriptions dispensed at the pharmacies (from 1995), laboratory measurement and causes of death are available.

Since 1950s, a unique personal identifier (civil registration number) has been assigned to every person at birth in Denmark, which allows linkage to all registries in Denmark on the individual level and provides full control over individual data on migration, residence and vital status - a prerequisite for an optimal study design. As a result, the entire Danish population is often considered as a cohort in epidemiological research. Although currently approximately 5.5 million Danes are alive, close to 9 million individuals can the tracked using the Danish Civil Registration System and close to 25% of these can be followed for more than 40 years.

Key references where this data system has been used in the AD field:

a. Sundbøll J, Horváth-Puhó E, Adelborg K, Schmidt M, Pedersen L, Bøtker HE, Henderson VW, Sørensen HT. Higher Risk of Vascular Dementia in Myocardial Infarction Survivors. Circulation. 2018 Feb 6;137(6):567-577.

b. Merete Osler, Gunhild T. Christensen, Ellen Garde, Erik L. Mortensen, Kaare Christensen. Cognitive ability in young adulthood and risk of dementia in a cohort of Danish men, brothers and twins. Alzheimers & Dementia. 2017 Dec;13(2017):1355-1363.

c. Corraini P, Henderson VW, Ording AG, Pedersen L, Horváth-Puhó E, Sørensen HT. Long-Term Risk of Dementia Among Survivors of Ischemic or Hemorrhagic Stroke. Stroke. 2017 Jan;48(1):180-186.

AD database characteristics for Denmark:

- Number of people age 60+ in the data system : 3.2 million
    - Among these, 43 million person years of observation
    - Median follow-up 12.8 years
- Number of people age 60+ in the data system with a diagnosis of AD : 220,000
    - 35,000 currently alive
    - Around 60% women among newly diagnosed (using the last year of data history)
    - Age distribution among newly diagnosed are slightly higher for women than men (82.9 years versus 80.7 years)

Strengths of the Danish data system:

- The ability to conduct studies with long follow-up, linked to other data sources and with complete control of censoring due to emigration or death.

- Linking healthcare registries with clinical trial data. Combing the best of the two worlds -the baseline randomization (trial part) and long-term event detection (registry part).
- General coverage - since the healthcare is free and tax-supported in Denmark, anyone is likely to be recorded regardless of, for instance, age or income (preventing some types of selection bias).

Limitations Danish data system

- Lack of detailed clinical data like measures of cognition and mental health.
- Low precision of some measurements and misclassification on disease codes.
- Limited data on lifestyle factors and no access to GP diagnoses (only diagnoses from hospital, ambulatory care and emergency room visits).

UK (THIN)

Pseudo-anonymised patient data are collected by THIN in a non-interventional way from the daily record keeping of general practices which use the Vision practice management software and have agreed to contribute to the scheme. The THIN database contains primary care medical records from over 12 million patients, of which over 3.8 million are actively registered.

THIN Data have been used extensively in medical research since 2003 in the UK, Europe and the United States, with over 500 peer review publications utilising the THIN data source. The age and gender profile of the active patient population in THIN has been shown to be comparable to the UK population. Data within THIN are regionally representative as far as is possible within the distribution of the Vision practice software from which they are collected, representing more than 6% of the UK population.

THIN Data have also been shown to be generally representative of the UK in terms of Quality and Outcomes Framework chronic disease parameters. In addition, a study has been performed which compares THIN with data from practices using a different general practice software system (EMIS) and it was shown to match closely with these data, with the main exception that THIN patients are slightly more highly representative of the more affluent social class. As this socioeconomic information is available in THIN, researchers are able to adjust for it in analyses.

Key references where THIN has been used in the AD field:

Strengths of the THIN system:

- The ability to conduct studies with long follow-up, linked to other data sources and with complete control of censoring due to emigration or death.
- Access to Primary care diagnoses and hospital diagnoses (by linkage to HES)
- Data on several factors that are often not recorded in large scale: life style factors, indications for treatment, dose and duration of treatments.

Limitations of the THIN system

- Lack of detailed clinical data related to AD like measures of cognition and mental health.
- Missing values on some of the measurements and misclassification on disease codes
- Limited data on hospital treatment

SPAIN (SIDIAP)

General practitioners (GPs) play an essential role in the public health care system of Spain, since they are responsible for primary health care, long-term prescriptions and specialist and hospital referrals. The public health care system covers more than 98% of the population in all Spain and the attendance rate achieved two thirds of the population in Catalonia (North-East Spain).

The Information System for Research in Primary Care (SIDIAP database) comprises electronic medical records of patients attended by 3,414 general practitioners from 274 primary care practices from the Catalan Health Institute (in Catalan, Institut Català de la Salut). SIDIAP covers a population of more than 5.6 million patients, which is about 80% of the Catalan population (and 10% of the Spanish population), and is highly representative of the population of Catalonia in terms of geographical, age and sex distributions.

The SIDIAP data comprise the clinical and referral events registered by primary care health professionals (general practitioners, nurses, and administrative staff). These electronic medical records include comprehensive demographic information, prescription and corresponding pharmacy invoicing data on pharmacological treatments, specialist referrals, primary care laboratory test results, and hospital admissions including cause of admission. Health professionals gather this information using ICD-10 codes and structured forms that are designed for the collection of variables relevant for primary care clinical management, such as country of origin, sex, age, height, weight, body mass index, tobacco and alcohol use, blood pressure measurements, and blood and urine test results. Encoding of personal and clinic identifiers ensures the confidentiality of the information in the SIDIAP database. SIDIAP consists of all the available clinical information from the general population. Therefore, it is important to develop rigorous posterior validation systems of the quality of data in order to adapt them to the specific needs for research.

SIDIAP is listed under the ENCePP resources database:

(www.encepp.eu/encepp/resourcesDatabase.jsp)

Key references where SIDIAP has been used in the AD field:

- María del Mar Garcia Gil, Rafel Ramos Blanes, Anna Ponjoan, Francesc Fina, Dolors Capellà, Rosa Morros, Xavier Castells, Buenaventura Bolivar. La enfermedad de Alzheimer y otras demencias en el sistema de información para el Desarrollo de la investigación en atención primaria (SIDIAP). Alzheimer Real Invet Demenc. 55, pp. 12 - 20. 2013.
- Anna Ponjoan, Josep Garre-Olmo, Jordi Blanch, Ester Fages, Lia Alves-Cabratosa, Ruth Martí-Lluch, Marc Comas-Cufí, Dídac Parramon, María del Mar Garcia-Gil, Rafel Ramos. Epidemiology of dementia: prevalence and incidence estimates using validated electronic health records from primary care. Sent to be published in Clinical Epidemiology.
- Josep Garre-Olmo, Anna Ponjoan, José Maria Inoriza, Jordi Blanch, Imma Sánchezc, Rafel Cubí, Rosa de Eugenio, Joan Vilalta-Franch on behalf of the Registry of Dementia of Girona Study Group (ReDeGi Study Group†). Prognosis, mortality rates, effect measures, and impact numbers after dementia diagnosis: a matched cohort study. Manuscript in preparation.

Strengths of the SIDIAP data system:

- SIDIAP includes longitudinal records of more than 5 million people and is highly representative of the Catalan population.

- SIDIAP is the biggest primary care database from Southern Europe and provides a unique opportunity to compare epidemiology of many conditions between Southern and Northern European populations.
- SIDIAP data have been externally validated for several conditions, such as cardiovascular risk factors, rheumatoid arthritis, cancer, or fragility fractures (www.sidiap.org). The ROADMAP project includes a use-case for the validation of the dementia diagnoses in SIDIAP.
- SIDIAP allows the linkage with external databases or registers. It has been linked with databases at the level of individuals in the assessment of several conditions such as mortality, cancer, arthroplasties, peripheral artery disease, dementia or hospitalizations; and at an ecological level to explore environmental exposure, such as atmospheric temperature, pollution, or greenness.
- SIDIAP is well connected with the corresponding health provider, which facilitates the implementation of measures to improve the quality of the information recorded in SIDIAP.

Limitations of the SIDIAP data system:

- SIDIAP is focused on clinical practice and the records are mainly concentrated on relevant events to patient's care, what could limit research topics.
- SIDIAP contains clinical data recorded by all general practitioners from the Catalan Health Institute. They enter data as part of their standard clinical practice and perhaps may not have the same level of awareness and motivation as in other databases where general practitioners who actively volunteer or are rewarded as data recorder specifically for research purposes.
- Lack of some social or demographic data of interest in several clinical conditions, such as literacy, economical status, and ethnicity.
- The common limitations of observational databases related to underreporting, misclassification or missing data.
- Limited use of free-text information. However, there is intense work in progress to improve the extraction of high-quality information from the free-text.

AD database characteristics in SIDIAP (at 31st December 2016):

- Number of people aged 60+ in the data system: 1.356.072 persons
- Among these, 14.664.445 person-years of observation
- Median follow-up of 11 years
- Number of people aged 60+ in the data system with a diagnosis of AD:

42.662 currently alive with AD

- Around 70.65% (N = 30.142) women among newly diagnosed (using the last year of data history)
- Age distribution varies according to sex. The percentages of new diagnoses according to age groups (60-69, 70-79, 80-89 and ≥90 years) were 4.3%, 20.9%, 57.5%, and 17% in women; and 7.5%, 28.8%, 53.7% and 9.9% in men, respectively.

The Netherlands (IPCI)

In 1992 the Integrated Primary Care Information Project (IPCI) was started by the Department of Medical Informatics of the Erasmus University Medical Center. IPCI is a longitudinal observational

database that contains data from computer-based patient records of a selected group of general practitioners (GPs) throughout The Netherlands, who voluntarily chose to supply data to the database. Collaborating practices are located throughout The Netherlands. The collaborating GPs are comparable to other GPs in the country according to age and gender. In the Netherlands, all citizens are registered with a GP practice, which forms the point of care and acts as a gatekeeper in a two-way exchange of information with secondary care. The medical records of each patient can therefore be assumed to contain all relevant medical information, including medical findings and diagnosis from secondary care.

The database contains information on about 2.2 million patients. This is the cumulative amount of patients who have ever been part of the dynamic cohort of patients who have been registered. The International Classification of Primary Care (ICPC) is the coding system for patient complaints and diagnoses, but diagnoses and complaints can also be entered as free text. Prescription data such as product name, quantity prescribed, dosage regimens, strength and indication are entered into the computer.(Vlug et al. 1999) The National Database of Drugs, maintained by the Royal Dutch Association for the Advancement of Pharmacy, enables the coding of prescriptions, according to the Anatomical Therapeutic Chemical (ATC) classification scheme recommended by the WHO.(2008)

As this is a primary care database, information on specialist prescribing, drug dispensing and actual drug intake is missing. IPCI is listed under the ENCePP resources database (www.encepp.eu/encepp/resourcesDatabase.jsp).

Other data systems in Europe

In the Netherlands, The PHARMO Database Network is a population-based network of electronic healthcare databases, which combines data from different primary and secondary healthcare settings. These different data sources, including data from general practices, in- and out-patient pharmacies, clinical laboratories, hospitals, the cancer registry, pathology registry and perinatal registry, are linked on a patient level through validated algorithms. Detailed information on the methodology and the validation of the used record linkage method can be found elsewhere (van Herk-Sukel et al 2010). The longitudinal nature of the PHARMO Database Network system enables to follow-up more than 4 million (25%) residents of a well-defined population in the Netherlands for an average of ten years. All electronic patient records in the PHARMO Database Network include information on age, sex, socioeconomic status and mortality. Other available information depends on the data source.

In Italy, the Health Search CSD Longitudinal Patient Database (HSD) was established in 1998 by the Italian College of General Practitioners (Filippi et al 2005). It is a longitudinal observational database that is representative of the Italian general population. The HSD contains data from computer-based patient records from a selected group of GPs (covering a total of 1.5 million patients) located throughout Italy. These GPs voluntarily agreed to collect data for the database and attend special training courses. The database includes information on the age, gender, and identification of the patient, and GP registration information, which is linked to prescription information, clinical events and diagnoses, hospital admission, and causes of death. Laboratory values are available.

Like Denmark, the other Nordic countries offer long-term follow-up of patients and complete control of censoring due to emigration or death. All Nordic countries have numerous nationwide registries, linkable on an individual level. They have over the past 25 years gathered a large number of registries and health care databases originating from routinely collected health care data. These

databases have originally been established for the purpose of planning, management, claims, and—albeit less often—research. One example of such a health care database is the various national prescription databases. They have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden, and since 2006 in Iceland.

Table 1. Overview over existing EHR data sources available in Europe

	NL	UK	DK	Spain	NL	Italy	The Nordics
Name of the database	IPCI	THIN	Government administered data	SIDIAP	PHARMO	HSD	Government administered data
Country and type of source	Netherlands, EMR	United Kingdom, EMR	Denmark, administrative data	Catalonia, Spain, EMR	NL / administrative data in a network	Italy, EMR	Sweden, Norway, Finland, Iceland, Denmark. Administrative data
Number of patients	2.2m	12.0m	5.4m	5.6m			25.0m
Cause of death	Yes	Yes	Yes	No	Yes	No	Yes
Outpatient prescriptions	Yes (specialist incomplete	Yes (specialist incomplete)	Yes	Yes (specialist incomplete)	Yes	Yes (specialist incomplete)	Yes
Coding of drugs	ATC	ATC	ATC	ATC	ATC	ATC	ATC
Dosing regimen	Yes	Yes	No	Yes	Yes	Yes	No
Hospitalizations	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Outpatient diagnoses	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Coding of disease	ICPC	READ	ICD-10	ICD-10	ICD-10	ICD-10	ICD-10

ADM = Administrative; ATC = Anatomical Therapeutic Chemical; BNF = British National Formulary; ICD= International classification of disease, ICPC = International Classification of Primary Care; MR = Medical Records

Reproduction of this document or part of this document without ROADMAP consortium permission is forbidden. Any use of any part must acknowledge the ROADMAP consortium as “ROADMAP Real world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform, grant agreement n°116020 (Innovative Medicines Initiative Joint Undertaking)”. This document is shared in the ROADMAP Consortium under the conditions described in the ROADMAP Consortium Agreement, Clause 9.

3.4. ROADMAP consortium accessible Cohort Overview

Information about numerous existing cohort data was already available in the EMIF AD and DPUK Catalogues or has been added now to the EMIF-AD Catalogue. This information was, together with additional cohort information generated by consortium data custodians, included in the Data Cube (see above). In addition to the meta-data about cohorts, several consortium members have also provided access to cohort data for specific research questions in WP4 and WP5. This includes the following cohorts (Table 2):

Table 2. Overview of data sources accessed within ROADMAP

Research purpose	**Data source**	**Location**
Validation of the pre-symptomatic AD model	4C and BBACL studies	The Netherlands
	PPSW & H70 studies	Sweden
	H70-study	Sweden
SIDIAP dementia diagnosis validation study	SIDIAP & ReDeGi	Spain
Validation of the MMSE model	IPCI	The Netherlands
	SIDIAP	Spain
	PPSW & H70 studies	Sweden
	EDAR	European multicentre study
	ICTUS	European multicentre study
	Memento	France
	Girona cohort	Spain
	Copenhagen database	Denmark
Pilot study: estimation costs of dementia	Amsterdam dementia cohort	The Netherlands
	DESCRIPA	European multicentre stucy
	ICTUS	European multicentre study
	ADNI	USA
	AIBL	Australia
Validation of the time to institutionalization model	ICTUS	European multicentre study
	4C study	The Netherlands
Mapping of quality of life instruments	Actifcare	The Netherlands
	LeARN	The Netherlands
BESIDE: Identifying care transitions and durations of different care trajectories of persons with dementia, and investigation of hospitalization	NIVEL-PCD	The Netherlands
	Statistics Netherlands	The Netherlands
	Dutch Hospital Data registry	The Netherlands

3.5. Clinical Trial Placebo Data Overview

Currently there is no single portal or place to identify potential clinical trial data available for a disease of interest. The researcher has to browse the clinical trial registries to identify studies of interest and subsequently approach the trial owners directly, or browe research and data sharing consortia for available trial data. That might change in the next few years, when EMA continues to operate the Clinical Data Portal to its full potential (https://clinicaldata.ema.europa.eu). Furthermore, clinical trial data are shared in private-public partnerships and consortia for specific research objectives (e.g. ROADMAP) or broader research programs (e.g. the CPAD consortium formerly known as CAMD https://c-path.org/programs/cpad/).

In order to create an initial overview of clinical trials conducted for MCI/Alzheimer's disease, two clinical trial registries were explored: ClinTrial.gov (https://clinicaltrials.gov) and the EU Clinical Trial Register (https://www.clinicaltrialsregister.eu/). Search and download functions ofClinTrial.gov are far more advanced than in the EU registry, which does not allow downloadingcomplete search results and has only limited pre-filtering functionality. Overall, there are 1932 Alzheimer's Disease (including MCI) studies registered in ClinTrial.gov and 324 in the EU clinical trial register. An overview of additional aspects of the registered trials in ClinTrial.gov are provided in **Figure 5** below. A more detailed list is attached as **Annex I** for the 536 industry-sponsored and completed Alzheimer's trials.



Figure 5. ClinTrial.gov Overview of Alzheimer's Disease studies (Aug 2018)

****e.g. Suspended, Terminated, Withdrawn, Unknown, Not recruiting***

Clinical Trial Data most often originate from the drug development programs of pharmaceutical companies and therefore are not easily shared with the research community. In the last few years this has changed to some degree, also due to upcoming changes in the regulators requirements to disclose not only study results and conclusions, but also aiming to disclose the data from which the results originate (see EU Clinical Trial Regulation EU 536/2014). The FDA is piloting similar approaches to enhance transparency, currently focusing on parts of the Clinical Study Report (see the FDA Clinical Data Summary Pilot Program - https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm589210.htm). The Biopharmaceutical

industry adopted the path into data sharing practices and established guidelines for best practices of data sharing (e.g. the PhRMA/EFPIA Principles for Responsible Clinical Trial Data Sharing) and discloses clinical trial data either through a single company access governance process, through an industry consortium entity (https://www.clinicalstudydatarequest.com), or through a private-public governance approach (http://yoda.yale.edu/).



Figure 6. Biopharmaceutical Industry Clinical Trial Data Sharing Pathways

Currently there are approximately 3900 clinical trials from 15 biopharmaceutical companies and some academic institutions available at ClinicalStudyDataRequest and among them, there are 27 trials with Alzheimer's disease indication. GSK contributed the majority of trials (18) and Lilly (4 trials) and Novartis (5 trials) are other contributors in this disease area. It is worth mentioning that all phases of the clinical development program (Phase 1 to 3) are included. There is a high variation in study duration as well as in numbers of study participants, showing general heterogeneity of the available clinical trial data landscape.

The Yale University Open Data Access (YODA - http://yoda.yale.edu/) Project currently hosts studies from 3 industry data custodians. There are 23 trials available for the Alzheimer's disease indication originating from Johnson&Johnson.

ClinicalDataStudyRequest as well as YODA maintain a list of available studies with search, browse and overview capabilities. Furthermore, ClinicalDataStudyRequest enables downloading the listing for additional custom filtering and identification of suitable studies, which includes details about available data formats (e.g. raw data, analysis datasets) and supporting documentation (e.g. annotated Case Report forms, analysis plan, protocol etc.). In addition, researchers are able to apply for clinical trials that are not listed.

Table 3 provides an overview of the disease stage covered as well as the number of patients and duration of the studies.

Table 3. Overview of Alzheimer's Disease CT data shared through ClinicalStudyDataRequest and YODA

ClinicalStudyDataRequest					
Sponsor	Study Drug	AD patient population	Duration	Number of sujects	Phase
GSK	GSK239512	mild moderate	29 days	28	Phase 1
		mild moderate	16 weeks	196	Phase 2
	GSK933776	mild and MCI	2 months	19	Phase 1
		probable (mild)	52 weeks	50	Phase 1
	Rilapladib	possible (MMSE score between 20 and 26 at Screening)	24 weeks	124	Phase 2
	Rosiglitazone	mild	single dose	14	Phase 1
		mild moderate	open-label extension 1 year	33	Phase 2
		mild moderate	12 months	80	Phase 2
		mild moderate	open-label extension 82 weeks	331	Phase 3
		mild moderate	open-label extension 48 weeks	422	Phase 2
		mild moderate	24 weeks	500	Phase 2
		mild moderate	24 weeks	862	Phase 3
		mild moderate	open-label extension 82 weeks	1461	Phase 3
		mild moderate	54 weeks	1468	Phase 3
		mild moderate	54 weeks	1496	Phase 3
Lilly	Semagacestat	mild moderate	29 weeks	45	Phase 3
		mild moderate	open-label extension 24 months	180	Phase 3
		probable	16 weeks	180	Phase 3
		probable	16 weeks	180	Phase 3
Novartis	Rivastigmine	MCI	48 months	1018	Phase 3
		mild moderate	48 weeks	1584	Phase 3
		probable	24 weeks	1040	Phase 3
		probable (MMSE 10-20)	24 weeks	859	Phase 3
		severe	24 weeks	716	Phase 4

YODA					
Sponsor	Study Drug	AD patient population	Duration	Number of sujects	Phase
Janssen	Galantamine	mild moderate	6 months	469	Phase 3
		mild moderate	9 months	144	Phase 3
		Alzheimer + vascular dementia	2-4 years	33	Phase 3
		Vascular dementia			
		mild moderate	4 months	130	
		mild moderate	5 months	979	Phase 3
		probable MCI	36 months	254	Phase 3
		severe	6 months	407	Phase 3
		MCI	24 months	1062	Phase 3
		MCI	24 months	974	Phase 3
		mild moderate	6 months	653	Phase 3
		mild moderate	6 months	636	Phase 3
		mild moderate	26 weeks	965	Phase 3
		probable mild moderate	3 months	387	Phase 3
		vascular and mixed dementia	7 months	593	Phase 3
		mild moderate	6 months	241	Phase 3
		mild moderate	16 weeks	215	Phase 3
		mild moderate	24 months	2051	Phase 3
		mild moderate	3 months	285	
		mild moderate	12 weeks	83	Phase 3
	Risperidone	MMSE 5-23	8 weeks	473	Phase 3

The majority of the trials include mild to moderate Alzheimer's disease patients. Severe Alzheimer's Disease as well as MCI is less well covered. A more detailed overview is provided in **Annex II**.

ROADMAP used CT placebo data, which were shared by one industry partner (Lilly) directly with the consortium. Data from four clinical trials were fingerprinted and are include in the ROADMAP data cube (link to Data cube).

3.6. Outcomes Reported by People Living with Dementia, Carers and Healthcare Professionals

This section gives an update on the types of AD-relevant real world data available on outcomes reported by people living with dementia, their caregivers, and healthcare professionals. Several of these outcomes are also included in the Data Cube as discussed above.

Core outcomes are those that are relevant to healthcare professionals, regulators and payers, but their selection should be guided by what matters to people with dementia and their caregivers. WP2 conducted a range of research, public involvement and review activities to define the priority outcomes – those that were most relevant to all key stakeholder groups. These were then used to produce a matrix classifying each outcome by the stage of disease severity. A mixed-methods analysis of results from all WP2 work streams resulted in the following core set of priority outcomes:

- Cognitive abilities

- Functional ability and independence
- Behavioural and neuropsychiatric symptoms
- Patient quality of life
- Quality of the carer's and family's lives

These five domains also represent the outcomes that people with dementia interviewed by WP2 identified as the most meaningful for identifying disease progression, its stage, or a meaningful delay.

Here, an additional focus will be on the availability of any data from patients, carers or healthcare professionals on:

- Adverse Events
- Experiences
- Preferences
- Adherence
- Socioeconomic factors

3.6.1. European real world data sources for AD-relevant outcomes reported by people living with dementia, carers and healthcare professionals

RWE appropriate outcomes data, including a variety of functional and behavioural measures, are available through ROADMAP consortium members (e.g., IMI PRISM, Dementias Platform UK, DPUK). ROADMAP has gathered information from relevant data sources and transferred this information to the EMIF AD Catalogue, a single-portal data resource for the discovery and validation of AD biomarkers. The complete overview of data availability and the 'Data Cube' are provided in D4.2.

In addition to performance outcome data from measurements based on tests and tasks administered by a healthcare professional and performed according to standard instructions (e.g., neuropsychological tests to assess memory or other cognitive functions), multiple real world sources contain patient- and carer-centred outcomes data. Beyond clinical research settings, and academic study cohorts, relevant data can be found in patient healthcare records, disease registries, and claims or billing records.

Patient-centred outcomes (PCOs) can (i) report on symptoms, daily activities, patient quality of life, experiences and preferences, (ii) measure the safety, efficacy, acceptability and cost-effectiveness of drugs or other interventions, or (iii) provide information on socioeconomic factors. Such information regarding patients' daily lives could benefit regulators, healthcare providers, payers, industry and the scientific community by informing pricing, research into disease mechanisms and progression, and the development of new treatments or the re-purposing of existing treatments.

Recent advances in digital health technology have opened new avenues in collecting real world data on symptoms and functional ability. Wearable devices and mobile applications allow continuous assessment and long-term monitoring of symptoms and daily activities, providing new ways to evaluate clinical effectiveness of treatments in real world settings.

3.6.2. Patient-reported outcomes (PROs)

PROs are based on self-reported information, or a patient's interview responses, about the patient's (study subject's) health, without any amendment or interpretation by the treating health care professional or anyone else. PROs are the only way to collect information about symptoms or other relevant events only known by the patient and not otherwise detectable using existing measurement tools and methods (e.g., intensity of pain). PROs are also used for obtaining measures on the patient perspective on certain aspects of functioning and living with dementia (e.g. trouble with memory and its impact, quality of life) that caregivers or other observers also report on. With the recent years' rapid progress in the application of digital technology to data collection, electronic PROs (ePROs) are already approved for clinical trial use in various health conditions.

3.6.3. Carer-reported outcomes (CROs)

Family members including spouses and children often act as study partners for the person with dementia, providing carer-reported outcomes (CROs). Although observers would normally only report on events or behaviours that they have witnessed, in studies where the person with dementia cannot respond for themselves (e.g., because they lack the mental capacity), observers may be asked to report on behaviours believed to reflect the symptom of interest, or to provide their opinion on different aspects of functioning and quality of life. Measurements on observer-reported outcomes (ObsROs) can also be based on observations by a paid carer or a health professional – anyone in a position to regularly observe the patient's health-related functioning in everyday life.

3.6.4. Clinician-reported outcomes (ClinROs)

ClinROs are ObsROs based on reports from trained health care professionals who have observed the patient and, thus, are able to comment on their health condition. ClinRO measurements on signs, behaviours or other manifestations of the disease or health condition are based on clinical observation, judgment and interpretation, and cannot inform on symptoms known only to the patient.

3.6.5. Carer-centred outcomes (CCOs)

Family and friends make enormous contributions to the management of dementia as informal carers. Whilst their need for greater support is increasingly recognised, there has been no consensus among stakeholders on which outcome measures to include in studies to assess the effects of caregiving on carers, including quality of life, family life, relationship with the person with dementia, relationships with others, mental health, perceived burden and ability to cope, sleep-wake rhythmicity, sleep quality, and the ability to adhere to dietary and physical activity recommendations.

A review investigating what would best support the sustenance of family caregiving and bolster carer resilience identified five critical themes: 1) extending social assets, 2) strengthening key psychological resources, 3) maintaining physical health status, 4) safeguarding quality of life, and 5) ensuring timely availability of key external resources (Parkinson, Carr, Rushmer, & Abley, 2016). Instruments addressing aspects of caregiving relevant to these themes could provide important measurements to evaluate the ability of existing services to adequately cater for carer needs – from carers' perspective.

The Zarit Burden Interview (ZBI) (Zarit, Reever, & Bach-Peterson, 1980) is a widely used measure of caregiver burden, with results presented as a unitary scale. As it was specifically designed to reflect

the stresses experienced by caregivers of dementia patients, the ZBI is considered to have particular utility.

The Impact of Alzheimer's Disease on Caregiver Questionnaire (IADCQ) (Cole et al., 2014) has been proposed as an alternative instrument to measure caregiver burden across emotional, physical, social, financial, sleep, and time aspects. It is a 12-item instrument with a seven-day recall period that can be administered over the web. Testing on 200 unpaid AD caregivers suggested that it can provide a suitable measure of the impact of caregiver burden, and that a single total-score interpretation of the results could be used as a valid measure.

Recent research has found caregiver burden to be multi-dimensional, and that uncertainty over the future is a novel factor of burden that needs further consideration. The development of new instruments to measure CCOs should take into account the diverse cultural and socioeconomic backgrounds, demographic characteristics and family constellations of those caring for people dementia around the world.

3.6.6. Data sources

Patient-centred and carer-centred data is mainly available from cohorts. Section 3.4 provided an overview of outcomes in all accessible cohort data. In addition, two survey data sources were used:

3.6.6.1. National Survey of Bereaved People

In the UK, the National Survey of Bereaved People is an annual survey commissioned by NHS England, designed to measure the quality of end of life care. The survey particularly focuses on the last three months of life and results are used to inform policy decisions and enable evaluation of the quality of end of life care by age group and sex, in different settings (home, hospital, care homes and hospices), and by different causes of death.

3.6.6.2. Health Survey for England (HSE)

The Health Survey for England (HSE) is a series of surveys, about the health of people living in England. The survey started in 1991 and has been carried out annually since then. It is currently commissioned by NHS Digital, and since 1994 has been carried out by the HSE team of the Health and Social Survey Research group at the Department of Epidemiology at UCL, in collaboration with NatCen Social Research. As well as gathering wider information covering psycho-social, demographic and socio-economic indicators, questions about use of health services and health data (e.g., weight, height, consumption of alcohol, smoking), each annual survey focuses on a particular population group, disease or condition. In 2000 and 2005 it looked at the health of older people; in other years it has looked at physical activity and fitness.

3.6.7. Availability of patient-centred data addressing the primary outcome domains

3.6.7.1. Cognitive abilities

Information about a patient's cognitive abilities typically comes from performance outcome measurements that are obtained from a test/task administered by a health care professional, according to standard instructions. The rater's clinical skills, attitude and ability to keep the patient engaged are important for obtaining reliable information on the level of functioning, as are the patient's alertness, motivation and cooperation. The core performance outcome measures in AD include tests of memory, language and communication, visuospatial ability, attention/executive functions,

intelligence, and other cognitive functions. The cohorts differ from EHR-based data sources in the availability of cognitive abilities outcomes data: This information is very limited in the EHR, but widely available for cohorts. Patient-centred measurements on cognitive abilities can be obtained by interviewing caregivers of people with dementia and in early disease stages also by interviewing the person with (or suspected of having) dementia.

3.6.7.2. Functional ability and independence

As is the case for cognitive abilities, outcomes data in the functional ability and independence domain are typically not available in the EHR (apart from SIDIAP). While cohort studies generally perform measurements on a variety of these outcomes, data availability is still limited on some aspects of activities of daily living (e.g., communication, transferring and self-efficacy).

3.6.7.3. Behavioural and neuropsychiatric symptoms

Rich and detailed information is also available from cohort studies on behavioural and neuropsychiatric symptoms. While the EHR-based sources also have data on some of these outcomes, this information is sometimes only saved as free text and therefore not readily available for quantitative analyses.

3.6.7.4. Patient quality of life (QoL)

Data on a range of outcomes related to patient QoL have been collected in cohort studies and are available to researchers via the EMIF AD Catalogue. This information is much less frequently available in EHR-based data sources. ROADMAP Use Case 6, based on a request from WP5 to identify data sources containing QoL instruments, found disease-specific QoL scale data for seven of the cohorts and general QoL scale data for 18 cohorts out of those included in the EMIF AD Catalogue and the DPUK Data Portal (see D3.4 for the details).

3.6.7.5. Quality of the carer's and family's lives

Data from cohorts in the EMIF AD Catalogue includes carer-centred outcome measurements on quality of life, perceived burden, stress, mood, social isolation, quality of relationships and other personal and social resources. However, information on carers' and families' QoL is generally very scarce relative to information on patients' QoL.

3.6.7.6. Adverse Events (AEs)

Data on AEs are available in the clinical trial placebo data accessible through consortium members. The CAMD Institute also provides access to placebo data that can be used for AD and MCI analyses. Information on side effects is available from EHR datasets, but is limited for cohort databases. In naturalistic studies required to demonstrate that the therapy works in real life, a PRO instrument could be used by physicians in standard clinical practice to collect information on AEs and side effects (Carreño et al., 2008). The characteristics of currently available data have been added to and fingerprinted in the EMIF AD Catalogue.

3.6.7.7. Experiences

In general, the inclusion of PRO instruments in studies to collect and share data on patients' experiences of and satisfaction with their therapy would allow comparisons between different health conditions and types of medications or other interventions. One such instrument is the Treatment Satisfaction Questionnaire for Medication (TSQM), which assesses patient experiences in three

domains: Effectiveness, Convenience, and Global Satisfaction (Atkinson et al., 2004; Bharmal et al., 2009).

Patientslikeme is a patient network and real-time research platform. Patients can use the network to connect with others who have the same disease or condition and share their own experiences to help improve outcomes and support future research. Researchers can access the data and the organisation has entered into research collaborations with a number of pharmaceuticals companies. Results have been shared via more than 100 research papers. There is some information accessible on the website on dementia medications, effectiveness and side effects, but a review of publications linked to Patientslikeme did not yield any findings directly relevant to AD. But as the service continues to develop this might change, and it may become a more useful source of data.

3.6.7.8. Preferences

Consideration of patient and caregiver preferences has become of increasing importance in the development of new interventions and treatment pathways. Although some data might be accessible from the data sources listed in 3.6.6 and from literature review, it is likely to be limited, and will require new primary research data to be collected.

Given the progressive nature of AD, end of life is an important consideration with regard to preferences. Data from the UK's National Survey of Bereaved People, an annual survey measuring the quality of end of life care is accessible for research purposes by filing an appropriate request to UK Data Service, an entity funded by the Economic and Social Research Council (ESRC) to meet the data needs of researchers in a variety of sectors. As part of the 2013 Views of Informal Carers - Evaluation of Services (VOICES), the Office of National Statistics conducted a survey on a stratified random sample of 49,607 people selected from 150,111 eligible registered deaths in England that year. Respondents (usually family members) were asked questions 4 and 11 months after the registered death, regarding the decedents' planning for death, preferences on place of death, and around support provided for care of dying persons at home (including pain relief). Dixon, King and Knapp (2016) performed a secondary analysis on these data, to investigate the effect of advance care planning (ACP) on outcomes. The decedents with a recorded preference for place of death had significantly greater odds of dying at home than in hospital.

Clarke et al. (2017) studied end of life treatment preferences by surveying a cross-sectional representative sample of the public in Great Britain and USA (n=2,016). The primary outcome measure was the respondents' preferences for care, as measured on a four-point scale from maintaining life at all costs through to choosing measures for ending life. They found no significant differences between the UK and USA, but noted the heterogeneous nature of the responses and the dichotomy between preserving life and the desire to die peacefully.

As there are currently no disease-modifying treatments for AD, considerations such as preferences for route of administration or avoidance of specific side effects are less central, but are important types of patient-centred information to collect where a range of treatments are available.

3.6.7.9. Adherence

Medication adherence (compliance) is normally considered to be the extent to which a patient acts in accordance with the prescribed interval and dose in a dosing regimen, and medication persistence the duration of time from initiation to discontinuation of therapy (Cramer et al., 2008). Adherence is affected by a range of patient- and medication-related and socio-economic factors (Yap, Thirumoorthy, & Kwan, 2016). For people living with AD, loss of cognitive capability is likely to be a factor, especially for those who do not have access to a caregiver. Insel et al (2006) studied

medication adherence in 95 elderly participants over 8 weeks. Participants were assessed for cognitive capability and a composite measure formed of executive function and working memory tasks was found to be the only significant predictor of adherence. (Molinuevo & Arranz, 2012) looked at the impact of transdermal drug (revastigmine) delivery on treatment adherence in people with AD and found increased adherence for those treated with patches rather than oral tablets.

Given the complexity of the factors that impact adherence and persistence, sources of data from cohort studies and other data repositories and unlikely to be that useful. No readily accessible sources of data were identified in the current work. However, PRO instruments assessing treatment satisfaction can provide important data. Patients' satisfaction with their medication has been shown to impact both their adherence with and willingness to continue to use that medication (Albrecht & Hoogstraten, 1998; McCracken, Klock, Mingay, Asbury, & Sinclair, 1997), critical factors in successful disease management and contributors to higher healthcare costs (Iuga & McGuire, 2014; Roebuck, Liberman, Gemmill-Toyama, & Brennan, 2011; Sokol, McGuigan, Verbrugge, & Epstein, 2005).

3.6.7.10. Socioeconomic factors

It is well recognised that socioeconomic factors throughout life have a role in dementia, but specific details are only starting to emerge from long-term studies. Russ et al. (2013) analysed 11 years of data from Health Survey for England (HSE) on individuals whose subsequent death was associated with dementia. They concluded that for women, but not men, leaving full-time education at an earlier age was associated with an increased risk of dementia – independent of common risk behaviours and comorbidities. Dementia death was not significantly associated with occupational social class in men or women.

3.6.8. Recent developments for collecting Patient Reported Outcomes data

3.6.8.1. Alternative trial designs

While the principal approach to long-term studies of product safety and effectiveness post-marketing has been extension studies, more cost-effective alternatives include non-interventional follow-on ("rollover") studies, which extend late-phase randomized controlled trials. Instead of relying on investigators to collect endpoint data over lengthy time periods, these studies ask patients to report events related to the endpoints of interest, which investigators can subsequently verify by contacting the treating health care professional. The frequency of follow-up and data collection methods can be adjusted to suit particular studies, and could include contact by phone, email, text message, or via an app. Collecting outcome data directly from patients could produce the evidence needed to convince payers and other stakeholders that the product works for real world patients, characterized by much more heterogeneity than is allowed in traditional clinical trials. However, this approach is not suited to collecting information on minor clinical events that the patient would not perceive as significant or that are not of critical importance as outcomes (cf. hospitalization). In dementia studies, an additional complication is the need to involve a study partner in the reporting of events and experiences in cases where this would be compromised by cognitive impairments.

3.6.8.2. Mobile technology, sensor-based monitoring and cloud computing

Some of the evidence gaps identified in the Data Cube (see D4.2 for the details) could be closed by digital data from studies that have incorporated wearable devices, mobile apps or other health technology, or from future studies that plan to collect such data. Approaches making use of digital technology could improve data collection and provide new real world relevant patient- outcomes in

the domains of cognitive abilities, functional ability and independence, behavioural symptoms, and neuropsychiatric symptoms. Moreover, the use of technology could help to fill gaps in the availability of carer-centred outcomes data on, for example, sleep patterns (at-home actigraphy) and quality of life (app-based self-reporting).

One of the main aims of WP3 has been to explore new opportunities from the recent advances in wearable and mobile technology solutions relevant to AD research. For example, the VUMC and RUG are conducting a feasibility study of a smartphone app-based passive behavioural monitoring for real world assessment of social communication and functioning in AD. The findings from this study are discussed in D3.5, which focuses on the utility of digital technology.

To be useful for measuring therapeutic effects in intervention trials, mobile or sensor technology-based approaches need to focus on clinically relevant events, accurately measure the right concept, be sensitive to change in the targeted patient cohort and at the right disease stage, and reliably index improvements due to the treatment. Any clinical benefits should also be meaningful to patients and carers and make a difference to their lives, (e.g., by improving patients' ADL capability and improving QoL).

Sensor-based collection of information could provide new clinical outcome assessment (COA) measurements and real world endpoints for clinical trials, for diagnostic purposes, tracking disease progression and monitoring symptoms, and for assessing the effects of a therapeutic intervention on the disease trajectory and particular symptoms (Teipel et al., 2018). Sensors installed in the home or worn by patients have the potential to provide valuable information on daily functioning (e.g. ability to perform household chores, walking, orientation, sleep) in real life settings. Sensor-based information on activities of daily living in particular would help to close some of the current data gaps and have potential to qualify as endpoints. A key strength of wearable devices and mobile applications compared with traditional in-clinic assessments is their ability to record continuous data over long time periods. Furthermore, devices or apps can be programmed to prompt a study participant to perform a particular action (e.g., take medication, prepare a meal), take a test, complete a scale, or respond to a particular question (e.g., What time did you wake up?). Collecting long-term continuous or serial data in real life settings not only allows better characterisation of everyday events as predictors of clinical events, but also early detection and treatment of behavioural and neuropsychiatric symptoms.

For COA based on information from various sources (e.g., patients, carers, clinicians, wearable and medical devices, diaries, voice recordings, images), eCOAs make use of technology for app-based data collection. As personalized reminders, upcoming visit information and site communications can be integrated into the app, this may boost compliance and reduce missing data.

Cloud technology systems such as MOVEeCloud (Digital Institute and MoveLab, Faculty of Medical Sciences, Newcastle University, UK) can be used for secure storage and analysis of physical activity, mobility and sleep data from accelerometers. Clinicians and other researchers can be given access to the data and measurements that the study team have stored in a cloud. Even if healthcare professionals could only view additional real world data from patients as summary information, this could inform the creation of personalized treatment plans, such as tailored physical activity targets.

In both app-based data collection and cloud computing, user privacy and data safety are considerations of utmost importance.

3.6.8.3. Big Data

Very large data sets containing patient level data on diagnoses, outcomes and care processes combined with computational power and advanced data analytics have the potential to advance

dementia research and outcomes-based health care. This could translate to improved outcomes for patients. ROADMAP is part of IMI's flagship Big Data for Better Outcomes (BD4BO) programme, which aims to advance sustainable, outcomes-driven healthcare. The DO-IT project provides a knowledge repository on big data topics (e.g., data management, outcomes selection) and BD4BO's work, as well as a toolkit with methodological and practical guidance on the identification and selection of outcomes into core outcome sets (COS), including those for use in real world settings. EHDEN is a real world data project aiming to map 100 million health records across the EU, using a common data model (OMOP). EHDEN will build a network of data sources, which will help BD4BO researchers find and use data effectively.

3.6.8.4. RADAR-AD

The EU's Horizon 2020 Societal Challenges call for Research and Innovation action within the Remote Assessment of Disease and Relapse (RADAR) programme includes the topic *Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer's Disease (RADAR-AD)*. Actions within this topic will assess the utility of technology including wearable and mobile devices and sensor-based home monitoring systems. This will consist of using existing longitudinal AD datasets and disease models to identify the functional domains (including real world activities) and markers that show sensitivity and specificity to disease progression in the early disease stages, as well as those that predict adverse outcomes (e.g. loss of independence and care home admission). In addition to seeking feedback from regulators regarding functional endpoints to be possibly considered for qualification for use in clinical trials, RADAR-AD actions will involve patients, caregivers and payers in the process of deciding which functional domains to measure. A platform technology-enabled functional assessment system will then be developed and wearable, smartphone, and/or home-based sensors used to collect continuous real world data in the selected functional domains. Finally, the assessment system will be validated in a clinical setting. This will require first establishing a reliable baseline measure for all disease stages, from cognitively normal through MCI and mild AD to moderate and severe AD.

3.6.9. Conclusions

RWE studies in dementia research provide the unique opportunity to obtain daily measurements, possibly reflecting fluctuations of cognitive abilities and functioning, as well as trajectories of disease progression over the long term (i.e., years). PROs are valuable in capturing the patient perspective on new treatments. However, even with pharmaceutical companies' interest in collecting and using PRO and CRO (perhaps also CCO) data, there are concerns that these will not be accepted by regulators or payers. This partly stems from a lack of consensus among stakeholders concerning the best procedures for validating approaches and data accuracy.

The application of wearable and mobile technology to outcome assessment in clinical practice and research requires valid methods for both data collection and analysis. Advanced analytical tools and data science approaches including machine and deep learning are increasingly being used, and will help to improve quality in this field. RADAR-AD actions could play a key role in moving towards regulatory approval of real world-measured functional endpoints. The report for D3.5 discusses the topic of digital technology in detail.

Another key challenge is how to best combine RWE data from different sources, for use in natural history and effectiveness research that goes beyond traditional clinical trial endpoints, investigates PROs with clinical and pharmacoeconomic outcomes, makes use of new digital technology solutions,

reflects the needs of patients and service providers, and is aligned with payer and regulatory guidelines and expectations. The report for D3.6 provides our guidelines on combining real world data.

References in section 3.6

Albrecht, G., & Hoogstraten, J. (1998). Satisfaction as a determinant of compliance. *Community Dentistry and Oral Epidemiology*, *26*(2), 139–146. https://doi.org/10.1111/j.1600-0528.1998.tb01940.x

Atkinson, M. J., Sinha, A., Hass, S. L., Colman, S. S., Kumar, R. N., Brod, M., & Rowland, C. R. (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. *Health and Quality of Life Outcomes*, *2*, 12. https://doi.org/10.1186/1477-7525-2-12

Bharmal, M., Payne, K., Atkinson, M. J., Desrosiers, M.-P., Morisky, D. E., & Gemmen, E. (2009). Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. *Health and Quality of Life Outcomes*, *7*, 36. https://doi.org/10.1186/1477-7525-7-36

Carreño, M., Gil-Nagel, A., Sánchez, J. C., Elices, E., Serratosa, J. M., Salas-Puig, J., … Porcel, J. (2008). Strategies to detect adverse effects of antiepileptic drugs in clinical practice. *Epilepsy & Behavior*, *13*(1), 178–183. https://doi.org/10.1016/j.yebeh.2008.02.006

Clarke, G., Fistein, E., Holland, A., Barclay, M., Theimann, P., & Barclay, S. (2017). Preferences for care towards the end of life when decision-making capacity may be impaired: A large scale cross-sectional survey of public attitudes in Great Britain and the United States. *PLOS ONE*, *12*(4), e0172104. https://doi.org/10.1371/journal.pone.0172104

Cole, J. C., Ito, D., Chen, Y. J., Cheng, R., Bolognese, J., & Li-McLeod, J. (2014). Impact of Alzheimer's Disease on Caregiver Questionnaire: internal consistency, convergent validity, and test-retest reliability of a new measure for assessing caregiver burden. *Health and Quality of Life Outcomes*, *12*, 114. https://doi.org/10.1186/s12955-014-0114-3

Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008). Medication Compliance and Persistence: Terminology and Definitions. *Value in Health*, *11*(1), 44–47. https://doi.org/10.1111/j.1524-4733.2007.00213.x

Dixon, J., King, D., & Knapp, M. (2016). Advance care planning in England: Is there an association with place of death? Secondary analysis of data from the National Survey of Bereaved People. *BMJ Supportive & Palliative Care*, bmjspcare-2015-000971. https://doi.org/10.1136/bmjspcare-2015-000971

Insel, K., Morrow, D., Brewer, B., & Figueredo, A. (2006). Executive function, working memory, and medication adherence among older adults. *The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences*, *61*(2), P102-7. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16497953

Iuga, A. O., & McGuire, M. J. (2014). Adherence and health care costs. *Risk Management and Healthcare Policy*, *7*, 35–44. https://doi.org/10.2147/RMHP.S19801

McCracken, L. M., Klock, P. A., Mingay, D. J., Asbury, J. K., & Sinclair, D. M. (1997). Assessment of satisfaction with treatment for chronic pain. *Journal of Pain and Symptom Management*, *14*(5), 292–299. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9392923

Molinuevo, J. L., & Arranz, F. J. (2012). Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease. *Expert Review of Neurotherapeutics*, *12*(1), 31–37. https://doi.org/10.1586/ern.11.178

Parkinson, M., Carr, S. M., Rushmer, R., & Abley, C. (2016). Investigating what works to support family carers of people with dementia: a rapid realist review. *Journal of Public Health*, *39*(4), e290–e301. https://doi.org/10.1093/pubmed/fdw100

Roebuck, M. C., Liberman, J. N., Gemmill-Toyama, M., & Brennan, T. A. (2011). Medication Adherence Leads To Lower Health Care Use And Costs Despite Increased Drug Spending. *Health Affairs*, *30*(1), 91–99. https://doi.org/10.1377/hlthaff.2009.1087

Russ, T. C., Stamatakis, E., Hamer, M., Starr, J. M., Kivimäki, M., & Batty, G. D. (2013). Socioeconomic status as a risk factor for dementia death: individual participant meta-analysis of 86 508 men and women from the UK. *British Journal of Psychiatry*, *203*(01), 10–17. https://doi.org/10.1192/bjp.bp.112.119479

Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005). Impact of medication adherence on hospitalization risk and healthcare cost. *Medical Care*, *43*(6), 521–530. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15908846

Teipel, S., König, A., Hoey, J., Kaye, J., Krüger, F., Robillard, J. M., … Babiloni, C. (2018). Use of nonintrusive sensor-based information and communication technology for real-world evidence for clinical trials in dementia. *Alzheimer's & Dementia*. https://doi.org/10.1016/J.JALZ.2018.05.003

Yap, A. F., Thirumoorthy, T., & Kwan, Y. H. (2016). Systematic review of the barriers affecting medication adherence in older adults. *Geriatrics & Gerontology International*, *16*(10), 1093–1101. https://doi.org/10.1111/ggi.12616

Zarit, S. H., Reever, K. E., & Bach-Peterson, J. (1980). Relatives of the impaired elderly: correlates of feelings of burden. *The Gerontologist*, *20*(6), 649–655. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7203086

4. Summary

Real World Evidence (RWE) outcomes include not only measurements based on tests and tasks administered by healthcare professionals. Relevant patient- and carer- centred outcomes can be found in both clinical and academic study cohorts as well as patient healthcare records, disease registries, and claims or billing records.

A list of relevant data sources was created and detailed information from these different sources was collected from existing data catalogues (EMIF, DPUK) and data custodians to provide an overview of available data in different data sources across the Alzheimer's disease spectrum (the Data Cube). All information was merged into a summary overview to identify high-level gaps in available priority outcomes in different data sources and data types. In general, most priority outcomes were available in all cohorts, EHR, and clinical trial placebo data. However, one should be aware of the limitations of each data source type, as different data source types are each best suited for examining different research questions. Information on cognitive abilities, functional abilities, behavioural and neuropsychiatric symptoms, and patient quality of life is often more widely and more detailed available in cohort studies compared to EHR sources. Still, data availability in cohorts is often limited on some aspects of activities of daily living. EHR sources generally do have some information available, albeit less detailed and often not readily available for quantitative analyses. In contrast, information on Adverse Events is available for most EHR and Clinical Trial Placebo data sources, while it is limited for cohort sources. EHR data sources are a particular powerful resource for tracking AD related comorbidities and they often facilitates long term follow-up of patients in large cohorts defined by a geographical area, a catchment area or a database system. To obtain real-world evidence from these data sources, one has to be aware of the many pitfalls and the context in which these data are generated. Cohort data sources often have biomarkers available to provide information on the etiology of cognitive impairments, as well as detailed neuropsychological assessments to provide information on different cognitive domains.

Our overview of data sources and the generated knowledge on data gaps in different data sources will guide future research in selecting appropriate data sources to answer specific research questions and/or may stimulate data custodians to collect additional data. Overall, this could benefit regulators, healthcare providers, payers, industry and the scientific community by informing pricing, research into disease mechanisms and progression, and the development of new treatments or the re-purposing of existing treatments. Recent advances in digital health technology may provide new opportunities to collect real world data on symptoms and functional ability in the near future.

ANNEXES

Reproduction of this document or part of this document without ROADMAP consortium permission is forbidden. Any use of any part must acknowledge the ROADMAP consortium as “ROADMAP Real world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform, grant agreement n°116020 (Innovative Medicines Initiative Joint Undertaking)”. This document is shared in the ROADMAP Consortium under the conditions described in the ROADMAP Consortium Agreement, Clause 9.

ANNEX I. ClinTrial.gov Study Overview

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT01715350	Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease	ADD	Alzheimer's Disease	Drug: PM012|Drug: Placebo	Phase 2	151	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 14	June 2015
NCT01529619	Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors		Alzheimer's Disease	Drug: Rivastigmine transdermal patch	Phase 4	52	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2013	December 2013
NCT00478205	Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease		Alzheimer's Disease	Drug: Aricept (donepezil SR 23 mg)|Drug: Aricept (donepezil IR 10 mg)	Phase 3	1467	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	June 2009	null
NCT00423085	Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Rivastigmine transdermal patch|Drug: Placebo	Phase 3	859	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	March 2009	Apr 10
NCT01227564	Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease		Alzheimer's Disease	Biological: ACC-001 3 Î¼g/ QS-21 50 Î¼g|Biological: ACC-001 10 Î¼g/ QS-21 50 Î¼g|Other: Placebo- Phosphate buffered saline (PBS)	Phase 2	63	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	February 2014	February 2014
NCT00082602	Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease		Alzheimer's Disease	Drug: galantamine ER	Phase 3	83	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	null	Apr 05
NCT00838110	A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Dimebon|Drug: Placebo	Phase 3	742	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	January 2010	January 2010
NCT01284387	Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease	ACCTION	Alzheimer's Disease	Biological: ACC-001 (vanutide cridificar)	Phase 2	126	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2014	February 2014
NCT02006641	Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil	STARBEAM	Alzheimer's Disease	Drug: Placebo|Drug: Idalopirdine	Phase 3	858	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	December 2016	December 2016
NCT01955161	Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil	STARSHINE	Alzheimer's Disease	Drug: Placebo|Drug: Idalopirdine	Phase 3	933	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	July 2016	July 2016
NCT02006654	Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor	STARBRIGHT	Alzheimer's Disease	Drug: Placebo|Drug: Idalopirdine	Phase 3	734	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	January 2017	January 2017
NCT01428362	VI-1121 for the Treatment Alzheimer's Disease	AD-201	Alzheimer's Disease	Drug: VI-1121|Drug: Placebo	Phase 2	61	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Aug 13	Aug 13
NCT01075763	A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease	REAL	Alzheimer's Disease	Drug: Interferon beta-1a|Drug: Placebo	Phase 2	42	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	May 2008	May 2008
NCT00867828	Neptune Krill Oil (NKOâ„¢) in Early Stage Alzheimer's Disease (MNEMOSYNE)	MNEMOSYNE	Early Onset Alzheimer Disease	Dietary Supplement: Neptune Krill Oil|Dietary Supplement: Fish Oil|Dietary Supplement: Placebo (soy oil)	Phase 4	175	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	July 2010	January 2011
NCT00934050	ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease		Alzheimer's Disease	Drug: ELND005 (scyllo-inositol)	Phase 2	103	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	June 2011	June 2011
NCT01193608	Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease		Alzheimer's Disease	Drug: AAB-003 (PF-05236812)|Other: Placebo	Phase 1	88	Interventional	Allocation: Randomized|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	October 2013	October 2013
NCT01369225	Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: AAB-003 (PF-05236812)	Phase 1	52	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Aug 14	Aug 14
NCT01254773	Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease	SUMMIT AD	Alzheimer's Disease	Drug: Experimental Bapineuzumab	Phase 2	146	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2013	March 2013
NCT00829374	Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil	CONCERT	Alzheimer's Disease	Drug: Dimebon|Drug: Placebo comparator	Phase 3	1003	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	December 2011	December 2011
NCT00230568	EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)		Alzheimer's Disease	Drug: Aricept	Phase 4	100	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Apr 07	December 2007
NCT02471196	Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease	Nebula	Alzheimer's Disease	Drug: ORM-12741|Drug: Placebo	Phase 2	308	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	October 9, 2017	December 4, 2017
NCT00911807	Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease	Combi	Alzheimer Disease	Drug: Cerebrolysin + donepezil|Drug: Cerebrolysin + placebo|Drug: Donepezil + placebo	Phase 2	217	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Apr 08	Apr 08
NCT00955409	Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease		Alzheimer Disease	Drug: ACC-001+ QS21|Drug: ACC-001|Drug: ACC-001 + QS21	Phase 2	50	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2013	December 2013
NCT00568776	ELND005 in Patients With Mild to Moderate Alzheimer's Disease		Alzheimer Disease	Drug: Placebo Control|Drug: ELND005	Phase 2	353	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2010	May 2010
NCT00959192	Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Biological: ACC-001|Other: QS-21	Phase 2	32	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2013	January 2013

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT00477659	Neural Correlates In Mild Alzheimer's Disease		Alzheimer's Disease	Drug: donepezil HCl (Aricept)	Phase 4	14	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Aug 08	Aug 08
NCT00752232	Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease		Alzheimer Disease	Biological: ACC-001|Other: QS-21|Other: PBS	Phase 2	40	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2012	July 2012
NCT00566501	Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease		Alzheimer's Disease	Drug: 23 mg SR in Study 326|Drug: 10 mg IR in Study 326	Phase 3	915	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Aug 10	Aug 10
NCT00575055	Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)		Alzheimer's Disease	Drug: Bapineuzumab 0.5 mg/kg|Drug: Placebo Control|Drug: Bapineuzumab 1.0 m/kg	Phase 3	1121	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Apr 12	Apr 12
NCT00574132	Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)		Alzheimer's Disease	Drug: Bapineuzumab 0.5 mg/kg|Drug: Placebo Control|Drug: Bapineuzumab 1.0 m/kg	Phase 3	1331	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	June 2012	June 2012
NCT00498602	Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease		Alzheimer Disease	Biological: ACC-001 + QS-21|Biological: QS-21|Other: Diluent: Phosphate Buffered Saline|Biological: ACC-001	Phase 2	160	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	February 2013	February 2013
NCT03456349	Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care		Alzheimer's Disease	Drug: HTL0018318|Drug: Placebo	Phase 1	60	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	July 16, 2018	July 16, 2018
NCT00035204	A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease		Alzheimer Disease	Drug: galantamine	Phase 4	63	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	May 2003
NCT01735630	Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease		Alzheimer's Disease	Drug: ELND005|Drug: Placebo	Phase 2	350	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2015	May 2015
NCT00571064	The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility		Mild to Severe Alzheimer's Disease	Drug: Donepezil HCl	Phase 4	97	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2008	April 22, 2009
NCT01614886	Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)		Alzheimer's Disease	Drug: Active Comparator|Drug: ENA713	Phase 3	216	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2014	May 2014
NCT00855868	Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals		Alzheimer's Disease	Drug: florbetapir F 18|Drug: [11C]-PIB	Phase 2	28	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	January 2011	January 2011
NCT00112073	AAB-001 in Patients With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: bapineuzumab|Other: placebo	Phase 2	234	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Nov 08	December 2008
NCT00104273	Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)		Dementia|Alzheimer's Disease	Drug: Rasagiline	Phase 2	376	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	March 2007	null
NCT00785759	Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers	ALZ201	Alzheimer's Disease|Amnestic Mild Cognitive Impairment	Drug: AH110690 (18F) Injection	Phase 2	78	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	March 2009	December 2009
NCT01662882	A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)		Alzheimer's Disease|Mild Cognitive Impairment	Drug: florbetapir (18F)	Phase 2|Pha	48	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	February 2013	February 2013
NCT01661673	Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease		Mild Cognitive Impairment|Alzheimer's Disease	Drug: EVP-0962|Drug: Placebo	Phase 2	52	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	October 2013	null
NCT00096473	Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease		Alzheimer's Disease|Dementia	Drug: Donepezil hydrochloride	Phase 3	229	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	June 2005	Sep 05
NCT01350362	Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients	ARGO	Alzheimer's Disease	Drug: tideglusib|Drug: Placebo	Phase 2	306	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2012	October 2012
NCT00338117	Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease		Alzheimer's Disease|Dementia	Drug: Galantamine hydrobromide	Phase 3	554	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	May 1997
NCT01073228	Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease|Central Nervous System Diseases|Cognition	Drug: EVP-6124|Drug: Placebo	Phase 2	409	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Nov 11	February 2012
NCT02097056	Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease	SAVE	Alzheimer's Disease	Drug: Donepezil HCL	Phase 4	171	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	May 2015	May 2015
NCT01908010	Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors		Alzheimer's Disease	Drug: ABT-354|Drug: Placebo	Phase 1	20	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Nov 13	Nov 13

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT01028053	Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease		Mild Cognitive Impairment|Alzheimer's Disease	Drug: Flutemetamol (18F) Injection	Phase 3	365	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	January 2014	January 2014
NCT00742417	Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid		Alzheimer's Disease	Biological: Albutein 5%|Other: Control	Phase 2	42	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	February 2011	March 2011
NCT01428453	A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease		Alzheimer's Disease	Drug: 250mg rilapladib|Drug: placebo	Phase 2	124	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	February 2013	February 2013
NCT02079909	Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)		Alzheimer's Disease	Drug: T-817MA-H|Drug: T-817MA-L|Drug: Placebo	Phase 2	484	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 5, 2017	May 5, 2017
NCT01254448	Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease		Alzheimer's Disease	Drug: TC-5619|Drug: Placebo	Phase 1	38	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary	March 2011	May 2011
NCT00762411	Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo	IDENTITY-2	Alzheimer's Disease	Drug: LY450139|Drug: Placebo	Phase 3	1111	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Apr 11	Apr 11
NCT02260674	A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease		Alzheimer's Disease	Drug: JNJ-54861911, 10 milligram (mg)|Drug: JNJ-54861911, 50 mg|Drug: Placebo	Phase 2	114	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	June 2016	June 2016
NCT01005862	Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers		Alzheimer's Disease	Biological: PF-04360365|Drug: Placebo	Phase 1	17	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Sep 12	Sep 12
NCT01406145	A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil		Alzheimer's Disease	Drug: ASP0777|Drug: Placebo	Phase 1	60	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Nov 11	Nov 11
NCT00945672	A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Biological: PF-04360365 10 mg/kg|Biological: PF-04360365 7.5 mg/kg|Drug: placebo	Phase 2	36	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	June 2011	June 2011
NCT00675090	Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: GSK239512|Drug: Placebo	Phase 1	28	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose:	June 16, 2009	June 16, 2009
NCT00733642	Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Biological: PF-04360365 1 mg/kg|Biological: PF-04360365 3 mg/kg|Biological: PF-04360365 5 mg/kg|Biological: PF-04360365 10 mg/kg	Phase 1	15	Interventional	Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	July 2009	July 2009
NCT00710684	A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease		Alzheimer's Disease	Drug: SB-742457 15mg|Drug: SB-742457 35mg|Drug: Placebo|Drug: donepezil 5-10mg	Phase 2	682	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	May 21, 2010	November 16, 2010
NCT00988598	A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: PF-04447943|Drug: Placebo	Phase 1	15	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2010	July 2010
NCT00731224	Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cmÂ² in Patients With Probable Alzheimer's Disease.	CARE	Alzheimer's Disease	Drug: Rivastigmine transdermal patch	Phase 4	380	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	October 2011	October 2011
NCT00357357	European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients		Alzheimer's Disease	Drug: HF0220	Phase 2	40	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Aug 08	Aug 08
NCT01424436	Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient		Alzheimer's Disease	Biological: GSK933776	Phase 1	19	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	December 8, 2011	December 8, 2011
NCT00381381	The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease		Alzheimer's Disease	Drug: Donepezil	Phase 4	199	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Aug 08	December 2008
NCT00757939	A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)		Alzheimer's Disease	Other: MRI|Other: FDG-PET	Phase 1	40	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	October 2010	October 2010
NCT02585934	Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study		Alzheimer's Disease	Drug: RVT-101|Drug: Placebo	Phase 3	1315	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 17	Sep 17
NCT02377713	A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.		Alzheimer's Disease	Drug: KHK6640|Drug: Placebo	Phase 1	20	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Sep 16	Sep 16
NCT01948791	16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients	INSTINCT	Alzheimer's Disease	Drug: ENA713	Phase 4	222	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sep 15	Sep 15
NCT00663936	Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: T-817MA|Drug: Placebo	Phase 2	373	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2011	June 2011

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT01850238	Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease		Alzheimer Disease	Biological: AADvac1|Other: Placebo	Phase 1	30	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	March 2015	March 2015
NCT00100334	Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimerâ€™s Disease		Alzheimer's Disease	Drug: PPI-1019 (APAN)	Phase 1|Pha	24	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	Aug 05
NCT00076440	Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study		Alzheimer Disease	Drug: Leuprolide acetate	Phase 2	90	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	March 2007	March 2007
NCT01054976	The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease		Alzheimer's Disease	Drug: Galantamine	Phase 4	99	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	February 2009	February 2009
NCT00645190	A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease		Alzheimer Disease	Drug: Galantamine HBr	Phase 3	215	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	February 2005
NCT00377715	Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Dimebon|Drug: Placebo	Phase 2	183	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Aug 06	null
NCT00100282	Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimerâ€™s Disease		Alzheimer's Disease	Drug: PPI-1019 (APAN)	Phase 1	125	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	June 2005
NCT00411580	Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)		Alzheimer's Disease	Biological: CAD106|Drug: Placebo	Phase 1	58	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2008	December 2008
NCT02094729	A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease		Alzheimer's Disease	Drug: BAN2401 2.5 mg/kg|Drug: BAN2401 5 mg/kg|Drug: BAN2401 10 mg/kg|Drug: Placebo	Phase 1	26	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	March 2015	May 2015
NCT00675623	A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease	CONNECTION	Alzheimer's Disease	Drug: Dimebon|Drug: Placebo	Phase 3	598	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2009	null
NCT00479557	Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease		Alzheimer Disease	Biological: ACC-001 + QS-21|Biological: ACC-001|Biological: QS-21|Drug: Placebo: Phosphate buffered saline	Phase 2	86	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2013	January 2013
NCT00309725	A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.		Alzheimer's Disease	Drug: galantamine	Phase 3	139	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	October 1999
NCT00301574	An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.		Alzheimer Disease	Drug: galantamine	Phase 3	398	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	February 2004
NCT03093519	A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease		Alzheimer Disease	Drug: KHK6640|Drug: Placebo	Phase 1	21	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	December 6, 2017	December 6, 2017
NCT00459550	A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease		Alzheimer's Disease	Drug: GSK933776|Drug: Placebo to match GSK933776	Phase 1	50	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	May 30, 2011	May 30, 2011
NCT00051909	Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease		Alzheimer's Disease	Drug: LY451395	Phase 2	200	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	June 2003
NCT00965588	Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease		Alzheimer's Disease	Biological: UB 311	Phase 1	19	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Apr 11	Apr 11
NCT01047579	A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of ExelonÃ® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease	BETTER	Alzheimer's Disease	Drug: Rivastigmine transdermal	Phase 4	51	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	January 2012	January 2012
NCT00381238	Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: rosiglitazone	Phase 2	33	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	February 1, 2009	February 3, 2009
NCT00414622	GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimerâ€™s Disease		Alzheimer Disease	Drug: DMXB-A	Phase 2	60	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	Apr 07
NCT00708552	Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease		Alzheimer's Disease	Drug: SB-742457|Drug: Donepezil|Drug: Placebo	Phase 2	576	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	March 1, 2010	March 9, 2010
NCT02907567	Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: CT1812|Drug: Placebo	Phase 1|Pha	19	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	August 24, 2017	Sep 17
NCT01374438	3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease		Alzheimer's Disease	Drug: MSDC-0160|Drug: Placebo	Phase 2	29	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	March 2013	May 2013
NCT02031198	18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease	FUNDAMANT	Alzheimer's Disease	Drug: AADvac1	Phase 1	25	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Aug 16	December 2016
NCT01978548	A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease		Alzheimer Disease	Drug: JNJ-54861911 10 mg|Drug: JNJ-54861911 50 mg|Drug: Placebo	Phase 1	45	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Apr 15	Apr 15

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT00722046	Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Biological: PF-04360365 0.1 mg/kg|Biological: PF-04360365 0.5 mg/kg|Biological: PF-04360365 1 mg/kg|Drug: Placebo|Biological: PF-04360365 3 mg/kg|Biological: PF-04360365 8.5 mg/kg	Phase 2	198	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Aug 11	Aug 11
NCT01689233	Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease		Alzheimer's Disease	Drug: TRx0237 200 mg/day|Drug: Placebo	Phase 3	800	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2016	May 2016
NCT03113812	Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients		Alzheimer's Disease	Drug: ABvac40|Drug: Placebo	Phase 1	24	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 30, 2015	July 30, 2015
NCT02560753	Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: T3D-959	Phase 1|Pha	36	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	May 30, 2016	June 30, 2016
NCT01689246	Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: TRx0237 150 mg/day|Drug: TRx0237 250 mg/day|Drug: Placebo	Phase 3	891	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Nov 15	Nov 15
NCT00219232	An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease		Alzheimer's Disease	Drug: Rivastigmine Transdermal Patch	Phase 3	868	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	July 2006	July 2006
NCT02986932	Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease	BBB-Alzheimers	Alzheimer Disease	Device: BBB opening	Not Applicat	6	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2017	December 2017
NCT00561392	Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease	ADEPT	Alzheimer's Disease	Drug: Rivastigmine 5 and 10 cm^2 patch	Phase 4	208	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Nov 08	Nov 08
NCT02240693	Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo		Alzheimer Disease	Drug: BI 409306|Drug: Placebo	Phase 2	128	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	September 18, 201	October 9, 2017
NCT01125631	Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Biological: PF-04360365 8.5 mg/kg|Drug: Placebo	Phase 1	8	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Aug 11	Aug 11
NCT00304629	Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease		Alzheimer Disease	Drug: galantamine	Phase 3	241	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	null	March 2002
NCT02754830	A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)		Alzheimer's Disease	Drug: LY3303560 - IV|Drug: Saline Solution - IV|Drug: LY3303560 - SC	Phase 1	110	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	July 10, 2018	July 10, 2018
NCT00087789	CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF	Phase 1	10	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	May 2010	May 2010
NCT00469456	Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease		Alzheimer's Disease	Drug: Memantine|Drug: placebo	Phase 4	265	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Nov 08	Nov 08
NCT00501111	Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease	Sirocco	Alzheimer Disease	Drug: AZD3480|Drug: Donepezil	Phase 2	659	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Aug 08	Aug 08
NCT02792179	Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants		Alzheimer's Disease	Drug: [18F]RO6958948	Phase 1	4	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	September 28, 201	September 28, 2016
NCT00622713	A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)	EXTRA	Alzheimer's Disease	Drug: Rivastigmine transdermal patch	Phase 4	228	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	January 2009	January 2009
NCT02820896	A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Placebo|Drug: RO7105705	Phase 1	74	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	June 26, 2017	June 26, 2017
NCT02389413	Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease	SAPHIR	Alzheimer's Disease	Drug: PQ912 oral|Other: Placebo	Phase 2	120	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Apr 17	Apr 17
NCT00285077	Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease		Alzheimer Disease	Drug: SR57667B	Phase 2	390	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Nov 06	Nov 06
NCT00842673	Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease		Alzheimer's Disease	Drug: ST101|Drug: Placebo	Phase 2	168	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 10	Sep 10
NCT00454870	Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: MEM 3454	Phase 2	80	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	October 2007	October 2007
NCT02431468	A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease		Alzheimer's Disease	Drug: Bryostatin 1|Other: Placebo	Phase 2	147	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	February 2017	February 2017
NCT00285025	Study of the Effect of SR57667B in Patients With Alzheimer's Disease		Alzheimer Disease	Drug: SR57667B	Phase 2	500	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	Sep 05
NCT00688207	Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)		Alzheimer's Disease	Drug: Rosiglitazone (Extended Release)	Phase 1	14	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sep 08	Sep 08

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT00842816	Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease		Alzheimer's Disease	Drug: ST101|Drug: Placebo	Phase 2	210	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2011	May 2011
NCT02434718	Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease	PROPEL	Alzheimer's Disease	Drug: Aducanumab|Drug: Placebo	Phase 1	21	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	December 9, 2016	December 9, 2016
NCT02386306	Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: GC021109|Other: Placebo	Phase 1	39	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	October 2015	October 2015
NCT02127476	A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: KHK6640|Drug: Matching Placebo	Phase 1	57	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2017	May 2017
NCT00277810	Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease		Alzheimer Disease	Drug: lecozotan SR (SRA-333)	Phase 2|Pha	250	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	June 2008	June 2008
NCT00930059	A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: PF-04447943|Drug: Placebo	Phase 2	198	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 10	Sep 10
NCT00744978	Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Varenicline|Drug: Placebo	Phase 2	66	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Nov 10	Nov 10
NCT02064920	Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)		Alzheimer's Disease	Drug: Placebo|Drug: Donepezil	Phase 2	36	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic	July 13, 2016	July 13, 2016
NCT01837641	A Study of LY3002813 in Participants With Alzheimer's Disease		Alzheimer Disease	Biological: LY3002813-IV|Biological: LY3002183-SC|Drug: Placebo-IV	Phase 1	100	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	August 24, 2016	August 24, 2016
NCT00348192	SB-742457 And Donepezil In Alzheimer's Disease		Alzheimer's Disease	Drug: SB-742457|Drug: donepezil	Phase 2	200	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	null
NCT02079246	Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease	STAR Extension	Alzheimer's Disease	Drug: Idalopirdine 60 mg	Phase 3	1463	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	July 6, 2017	July 6, 2017
NCT00063310	ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation		Alzheimer Disease	Drug: Leuprolide acetate	Phase 2	90	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	February 2006	February 2006
NCT01565343	A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers		Alzheimer's Disease	Drug: florbetapir F 18	Phase 1	25	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose:	Apr 09	Apr 09
NCT01009255	Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease		Alzheimer's Disease	Drug: GSK239512|Drug: Placebo	Phase 2	196	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	November 10, 201	November 10, 2010
NCT01565291	A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers		Alzheimer Disease	Drug: florbetapir F 18	Early Phase	32	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	January 2008	January 2008
NCT01723826	A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab		Alzheimer's Disease	Drug: Crenezumab	Phase 2	360	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	February 8, 2017	February 8, 2017
NCT01565330	A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers		Alzheimer Disease	Drug: florbetapir F 18	Phase 1	20	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose:	Aug 08	Aug 08
NCT01548430	A Safety Study of TTP4000 in Subjects With Alzheimer's Disease		Alzheimer's Disease	Drug: TTP4000|Drug: Placebo	Phase 1	8	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)	February 2013	February 2013
NCT01324518	Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease	ALPO	Alzheimer's Disease	Drug: ORM-12741|Drug: Placebo for ORM-12741	Phase 2	100	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 12	October 2012
NCT01527916	Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: placebo|Drug: donepezil|Drug: ABT-126	Phase 2	438	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Nov 13	Nov 13
NCT01677754	A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy	MAyflOwer RoAD	Alzheimer's Disease	Drug: RO4602522|Drug: Placebo|Drug: Donepezil|Drug: Memantine|Drug: Rivastigmine|Drug: Galantamine	Phase 2	542	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	June 12, 2015	June 12, 2015
NCT01482845	A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease		Alzheimer's Disease	Drug: ABT-126|Drug: Placebo	Phase 1	20	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)	March 2012	March 2012
NCT01397539	Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease		Alzheimer's Disease	Drug: BIIB037|Other: Placebo	Phase 1	53	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose:	Aug 13	Aug 13
NCT00224497	A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease		Alzheimer's Disease	Drug: SB-742457	Phase 2	380	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	null
NCT00093951	SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)		Alzheimer's Disease	Drug: SGS742	Phase 2	280	Interventional	Allocation: Randomized|Masking: Double|Primary Purpose: Treatment	Sep 07	Sep 07
NCT01179373	Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease		Alzheimer's Disease	Device: TMS, H coil	Phase 2	45	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	January 2015	June 2015
NCT01496170	A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])		Alzheimer's Disease	Drug: MK-8931|Drug: Placebo	Phase 1	32	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	June 2012	June 2012

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT01549834	Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors		Alzheimer's Disease	Drug: ABT-126|Drug: placebo	Phase 2	434	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	October 2013	October 2013
NCT01492374	Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease		Alzheimer's Disease	Drug: BMS-241027|Drug: Placebo matching BMS-241027	Phase 1	40	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	October 2013	October 2013
NCT01343966	A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)		Alzheimer's Disease	Drug: MABT5102A|Drug: placebo	Phase 2	448	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	February 28, 2014	February 28, 2014
NCT01399125	A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease		Alzheimer's Disease	Drug: Rivastigmine Patch|Drug: Rivastigmine Capsules|Drug: Placebo to Rivastigmine patch|Drug: Placebo to Rivastigmine capsules	Phase 3	501	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2013	May 2013
NCT01397578	A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: MABT5102A|Drug: placebo	Phase 2	91	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	April 30, 2014	April 30, 2014
NCT00097916	An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease		Alzheimer's Disease	Drug: memantine HCl	Phase 3	34	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	Apr 06	Apr 06
NCT00904683	Effect of LY2062430 on the Progression of Alzheimer's Disease	EXPEDITION2	Alzheimer's Disease	Drug: LY2062430|Drug: Placebo	Phase 3	1040	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	June 2012	June 2012
NCT01137526	Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: ABT-384|Drug: donepezil|Drug: placebo	Phase 2	267	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	July 2011	July 2011
NCT00880412	A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease	EHT0202/002	Alzheimer's Disease	Drug: EHT 0202 etazolate|Drug: Placebo	Phase 2	197	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	June 2009	Aug 09
NCT00905372	Effect of LY2062430 on the Progression of Alzheimer's Disease	EXPEDITION	Alzheimer's Disease	Drug: LY2062430|Drug: Placebo	Phase 3	1000	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Apr 12	Apr 12
NCT01019421	Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Lu AE58054|Drug: Placebo	Phase 2	278	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	December 2011	null
NCT00265148	Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease		Alzheimer's Disease	Drug: Rosiglitazone|Other: Placebo	Phase 2	80	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	July 2008	July 2008
NCT00348309	Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease	REFLECT-2	Alzheimer's Disease	Drug: Rosiglitazone Extended Release 2mg|Drug: Rosiglitazone Extended Release 8mg|Other: Placebo|Other: Donepezil	Not Applicat	1496	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 1, 2009	January 28, 2009
NCT00818662	A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate AlzheimerÂ´s Disease		AlzheimerÂ´s Disease	Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg|Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg	Phase 3	390	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	December 2012	December 2012
NCT01018875	Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: ABT-288|Drug: donepezil|Drug: placebo	Phase 2	242	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	February 2011	February 2011
NCT00165724	Alzheimer's Disease Long-term Follow-up Study (ALF Study)		Alzheimer's Disease	Drug: Donepezil Hydrochloride	Phase 4	114	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	July 2006	December 2006
NCT00056628	COGNIShuntÂ® System for Alzheimer's Disease		Alzheimer Disease	Device: The COGNIShuntÂ® System	Phase 3	250	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	null	October 2004
NCT00749216	Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease		Alzheimer's Disease	Drug: Solanezumab	Phase 2	33	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	July 2009	July 2009
NCT00804271	Memantine and Validation of a New Alzheimer's Disease Scale		Alzheimer's Disease	Drug: memantine	Phase 3	487	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)	Nov 09	Nov 09
NCT00948909	Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Placebo|Drug: ABT-126|Drug: donepezil	Phase 2	274	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Nov 10	Nov 10
NCT00684944	Open Label Study of TRx0014 in Alzheimer's Disease		Alzheimer's Disease	Drug: TRx0014	Phase 2	111	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2, 2010	December 2, 2010
NCT00384423	Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept		Alzheimer's Disease	Drug: PRX-03140	Phase 2	80	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	October 2007	null
NCT01117818	Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease		Alzheimer's Disease	Biological: active: AFFITOPE AD02|Biological: control: Placebo	Phase 2	335	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2013	December 2013

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT00234637	Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment		Alzheimer's Disease	Drug: Rivastigmine, memantine	Phase 4	204	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	June 2005	June 2005
NCT00594568	Effect of LY450139 on the Long Term Progression of Alzheimer's Disease		Alzheimer's Disease	Drug: LY450139|Drug: Placebo	Phase 3	1537	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2011	May 2011
NCT02337907	BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.		Alzheimer Disease	Drug: Placebo|Drug: BI 409306|Drug: Donepezil	Phase 2	329	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	September 15, 201	October 10, 2017
NCT00948259	Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With AlzheimerÂ´s Disease		AlzheimerÂ´s Disease	Drug: NP031112|Drug: Placebo	Phase 1|Pha	30	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Nov 09	Nov 09
NCT00884507	A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Placebo|Drug: RO5313534	Phase 2	389	Interventional	Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Nov 10	Nov 10
NCT02185053	A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia		Alzheimer's Disease	Drug: CPC-201	Phase 2	41	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	July 2016	July 2016
NCT01039701	4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease	ROBIN	Mild to Moderate Alzheimer's Disease	Drug: AZD1446|Drug: Placebo	Phase 2	99	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	July 2010	July 2010
NCT02423200	Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD		Alzheimer's Disease	Drug: VX-745	Phase 2	16	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 16	Nov 16
NCT00104442	Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease		Alzheimer's Disease	Drug: Rivastigmine	Phase 4	80	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	null	Apr 06
NCT00348140	Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease	REFLECT-3	Alzheimer's Disease	Drug: Rosiglitazone Extended Release 2mg|Drug: Rosiglitazone Extended Release 8mg|Other: Placebo	Phase 3	1468	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	March 20, 2009	March 20, 2009
NCT00423228	Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease	BRAINz	Moderate Alzheimer's Disease	Drug: ZT-1|Drug: Donepezil	Not Applicat	228	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Apr 09	Apr 09
NCT00443417	A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: SK-PC-B70M	Phase 2	188	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2009	January 2009
NCT00000172	Evaluation of Galantamine in the Treatment of Alzheimer's Disease		Alzheimer Disease	Drug: Galantamine	Phase 3	null	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	null
NCT00810147	A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: BMS-708163|Drug: Placebo	Phase 2	209	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	June 2010	June 2010
NCT00428090	Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Rosiglitazone	Phase 3	862	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	September 1, 2008	September 5, 2008
NCT00630851	A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes		Alzheimer Disease	Drug: Donepezil (Aricept)|Drug: Placebo	Phase 3	249	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	October 2004
NCT00464334	A Study of V950 in People With Alzheimer Disease (V950-001 AM7)		Alzheimer Disease	Biological: V950|Biological: ISCOMATRIXâ„¢|Biological: Placebo to V950	Phase 1	86	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic	January 2012	January 2012
NCT00334906	Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)		Alzheimer's Disease	Drug: memantine HCl	Phase 4	75	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Nov 07	null
NCT00814801	An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease		Alzheimer's Disease	Drug: Placebo|Drug: Galantamine 16 mg/day|Drug: Galantamine 24 mg/day	Phase 3	580	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	Sep 08	Sep 08
NCT00566397	A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: PF-04494700|Drug: Placebo	Phase 2	402	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2010	December 2010
NCT00736775	A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease		Alzheimer's Disease	Drug: anti-Abeta|Drug: placebo	Phase 1	56	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	May 2010	null
NCT00420420	MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)		Alzheimer's Disease	Drug: MK0249|Drug: Comparator: Placebo (unspecified)	Phase 2	144	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Aug 08	Aug 08
NCT00607308	A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Biological: PF-04360365|Drug: Placebo	Phase 1	20	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	October 2010	October 2010
NCT00481520	Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease		Alzheimer Disease	Drug: SAM-531|Other: placebo	Phase 2	72	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)	January 2008	January 2008
NCT00471211	Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease		Alzheimer's Disease	Drug: PBT2	Phase 2	80	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	December 2007	December 2007

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT00455000	A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease		Alzheimer's Disease	Biological: PF-04360365|Drug: Placebo	Phase 1	37	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Sep 09	Sep 09
NCT00397891	Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease		Alzheimer Disease	Drug: bapineuzumab	Phase 1	80	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	February 2010	February 2010
NCT00549601	Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease	KAPA	Alzheimer's Disease	Drug: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Drug: Rivastigmine patch (9.5 mg/day)|Drug: Rivastigmine capsules (6 mg to 12 mg/day)	Phase 4	142	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Apr 09	Apr 09
NCT00142805	Ketasyn in Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Ketasynâ„¢ (AC-1202)	Phase 2	100	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	March 2006
NCT02187627	Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants		Alzheimer's Disease, Healthy Volunteer	Drug: [11C]RO6924963|Drug: [11C]RO6931643|Drug: [18F]RO6958948	Phase 1	52	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	February 2016	February 2016
NCT00191009	Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease		Alzheimer Disease	Drug: atomoxetine hydrochloride|Drug: placebo	Phase 2|Pha	124	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	January 2006
NCT00359944	Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: AC-3933|Other: Sugar Pill	Phase 2	171	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Sep 08	Sep 08
NCT00428389	Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease		Alzheimer's Disease	Drug: Rivastigmine 5 cm^2 transdermal patch|Drug: Rivastigmine 10 cm^2 transdermal patch	Phase 3	262	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	February 2008	February 2008
NCT00083421	Effects of ONO-2506PO in Patients With Alzheimer's Disease		Alzheimer's Disease	Drug: ONO-2506PO	Phase 2	647	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	July 2007
NCT00231946	ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)		Alzheimer's Disease	Drug: VP4896	Phase 3	555	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	null
NCT00257673	Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: MEM 1003|Drug: Placebo for MEM 1003	Phase 2	183	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	October 2007	October 2007
NCT00633841	Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Biological: AFFITOPE AD02	Phase 1	24	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Sep 09	Sep 09
NCT00151398	Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)		Alzheimer Disease	Drug: lecozotan SR|Drug: Donepezil	Phase 2	229	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	March 2008	March 2008
NCT00151333	Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)		Alzheimer's Disease	Drug: SRA-333	Phase 2	16	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	Apr 05	Apr 05
NCT00305903	Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease		Alzheimer's Disease	Drug: Rivastigmine, memantine	Phase 4	150	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	null	Aug 07
NCT01013610	An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease		Mild Alzheimer's Disease	Drug: LNK-754|Drug: Placebo	Phase 1	110	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)	March 2011	March 2011
NCT00495417	Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Biological: AFFITOPE AD01|Biological: AFFITOPE AD01 adjuvanted	Phase 1	24	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Aug 09	Aug 09
NCT00329082	Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers		Alzheimer's Disease	Drug: LY2062430|Drug: Placebo	Phase 2	25	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	May 2008	May 2008
NCT00244322	Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: LY450139 dihydrate|Drug: placebo	Phase 2	45	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic	null	December 2006
NCT00090116	The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease		Alzheimer's Disease	Drug: Neramexane	Phase 3	400	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	March 2005	March 2005
NCT00074529	Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)		Alzheimer's Disease	Drug: MK0677	Phase 2	512	Interventional	Allocation: Randomized|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	January 2006	January 2006
NCT01701089	A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers		Healthy Volunteer, Alzheimer's Disease	Drug: 11C-L-deprenyl-D2|Drug: RO4602522	Phase 1	17	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	May 2013	May 2013
NCT00862940	A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease		Alzheimer's Disease	Drug: Memantine|Drug: Placebo	Phase 4	277	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	February 2009	Apr 09
NCT00319891	Computer-Based Training for Mild Alzheimer's Disease		Alzheimer's Disease	Procedure: Computer-based Cognitive Training	Phase 1	6	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	October 2006	October 2006
NCT00812565	Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: Placebo|Biological: octagam 10%	Phase 2	58	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 10	Sep 10
NCT00506415	Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline		Alzheimer Disease	Drug: Rivastigmine 5 cm^2|Drug: Rivastigmine 10 cm^2|Drug: Rivastigmine 15 cm^2|Drug: Placebo to 15 cm^2 patch|Drug: Placebo to 10 cm^2 patch	Phase 3	1584	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	May 2011	May 2011

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT02360657	Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia		Alzheimer's Disease	Drug: JNJ-54861911, 10 mg|Drug: JNJ-54861911, 50 mg|Drug: Placebo	Phase 1	18	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Sep 15	Sep 15
NCT00976118	Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: masitinib (AB1010)|Drug: placebo	Phase 2	34	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2008	February 2009
NCT02546310	Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects		Alzheimer's Disease	Drug: HTL0009936|Drug: HTL0009936 matching placebo	Phase 1	54	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic	February 2017	February 2017
NCT02537938	Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)		Alzheimer's Disease	Drug: NGP 555	Phase 1	24	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	December 2016	December 2016
NCT01466088	Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)		Alzheimer's Disease	Drug: Donepezil|Drug: AZD3480	Phase 2	386	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2014	May 2014
NCT00130429	Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease		Alzheimer's Disease	Drug: PYM50028	Phase 2	250	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	Sep 05
NCT01600859	Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)		Alzheimer's Disease	Drug: E2609|Drug: Placebo for E2609	Phase 1	65	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Sep 13	October 2013
NCT02035553	A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis		Alzheimer's Disease Psychosis	Drug: Pimavanserin tartrate|Drug: Placebo	Phase 2	181	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	September 28, 201	October 27, 2016
NCT01485302	Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients		Alzheimer's Disease	Drug: SAR228810	Phase 1	48	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	February 2015	February 2015
NCT00843518	Treatment for Aggression and Agitation in Patients With Alzheimer's Disease		Alzheimer's Disease	Drug: LY451395|Drug: Placebo	Phase 2	132	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	June 2011	June 2011
NCT02040987	AZD3293 Thorough QT Study in Healthy Male Volunteers	AZD3293TQT	Alzheimer's Disease Alzheimer	Drug: AZD3293|Drug: Placebo|Drug: Moxifloxacin	Phase 1	52	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	May 2014	May 2014
NCT00750282	Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral Î²-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers		Disease|Amyloid Beta-Protein	Drug: Florbetaben (BAY94-9172)	Phase 2	422	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Nov 10	Nov 10
NCT01478633	Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil		Alzheimer's Disease	Drug: Galantamine	Phase 4	102	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	June 2013	June 2013
NCT01660815	A Study of Florbetapir (18F) in Japanese Healthy Volunteers		Alzheimer's Disease	Drug: florbetapir (18F)	Phase 1	7	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	January 2013	January 2013
NCT01807026	A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease		Alzheimer Disease|Healthy Volunteers	Drug: LY2886721|Drug: Placebo	Phase 1	36	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	May 2013	May 2013
NCT00099242	Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease		Alzheimer's Disease|Dementia, Alzheimer Type	Drug: rivastigmine transdermal patch	Phase 3	1040	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	January 2006
NCT00948766	Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44	ACTION	Alzheimer's Disease	Drug: Rivastigmine 4.6 mg/24 h (5 cm^2)|Drug: Rivastigmine 9.5 mg/24 h (10 cm^2)|Drug: Rivastigmine 13.3 mg/24 h (15 cm^2)|Drug: Placebo	Phase 4	716	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2012	June 2012
NCT01035164	Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers		Positron-Emission Tomography|Alzheimer's Disease	Drug: F-18 FEDAA1106 (BAY85-8101)	Phase 1	25	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	January 2010	January 2010
NCT01024660	The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil		Alzheimer's Disease	Drug: Donepezil|Drug: Placebo to match Aricept	Early Phase	155	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic	January 2011	January 2011
NCT01928420	A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease		Alzheimer's Disease|Dementia	Drug: Drug: NIC5-15|Drug: Placebo	Phase 2	30	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	June 2014	June 2014
NCT01002079	Drug-Drug Interaction Study With Rifampin		Alzheimer Disease	Drug: BMS-708163|Drug: Rifampin	Phase 1	20	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	October 2010	October 2010
NCT02703636	NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.	ENA1stepswitch	Mild to Moderate Alzheimer's Disease	Drug: Rivastigmine Patch	Phase 4	118	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	May 7, 2018	May 7, 2018
NCT01513967	A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease		Moderate to Severe Alzheimer|Alzheimer Disease	Drug: RPh201, botanical drug product|Drug: Placebo|Drug: RPh201, botanical extract product	Phase 1|Pha	36	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	June 2015	June 2015
NCT02249403	Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type		Alzheimer Disease	Drug: Talsaclidine 6 mg|Drug: Talsaclidine 12 mg|Drug: Talsaclidine 24 mg|Drug: Talsaclidine 36 mg|Drug: Placebo	Phase 2	362	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	January 2000	null

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT02992132	Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)		Agitation and Aggression in Alzheimer's Disease	Drug: Pimavanserin 34 mg|Drug: Pimavanserin 20 mg|Other: Placebo	Phase 2	111	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 25, 2018	February 16, 2018
NCT00216515	The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type		Alzheimer Disease	Drug: galantamine hydrobromide	Phase 4	102	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	null	Nov 05
NCT00467766	Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimerâ€™s Disease		Alzheimer Disease|Caregivers	Behavioral: Psychosocial information, counseling, and support|Drug: Donepezil (Aricept)	Not Applicat	300	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment	null	June 2003
NCT02036645	SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.		Mild-Moderate Alzheimer's Disease|Healthy Elderly	Biological: MEDI1814 for IV injection|Biological: MEDI1814 for Subcutaneous Injection|Biological: IV Placebo|Biological: Placebo for Subcutaneous Injection	Phase 1	219	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science	Sep 16	Sep 16
NCT00829816	Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil		Alzheimer's Disease	Drug: Dimebon|Drug: Placebo	Phase 1	46	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Apr 09	Aug 10
NCT01436188	A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease		Healthy|Alzheimer Disease	Procedure: Standard CSR sampling procedure|Procedure: Alternate frequency CSR sampling procedure|Procedure: Standard frequent CSR sampling procedure with 800 mg ibuprofen|Procedure: Alternative lower frequency CSR sampling procedure	Early Phase	5	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)	null	June 2013
NCT00880347	Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia		Alzheimer's Disease|Dementia	Device: Blood sampling	Not Applicat	550	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	February 2011	February 2011
NCT01764243	Safety and Efficacy of MT-4666		Alzheimer's Disease	Drug: MT-4666|Drug: Placebo	Phase 2	450	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	June 2015	July 2015
NCT00380302	Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.		Alzheimer Disease	Drug: AVE1625	Phase 1|Pha	162	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	July 2007	July 2007
NCT02392468	Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers		Schizophrenia|Alzheimer Disease	Drug: BI 409306 matching placebo|Drug: BI 409306	Phase 1	61	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	August 10, 2017	August 10, 2017
NCT01453569	Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease		Alzheimer Disease|Cognitive Impairment	Drug: Sodium oligo-mannurarate 600mg|Drug: Sodium oligo-mannurarate 900mg|Drug: Placebo	Phase 2	255	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Aug 13	Aug 13
NCT01380288	Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine	CAREER	Alzheimer's Disease	Drug: rivastigmine patch	Not Applicat	300	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2016	December 31, 2017
NCT00253214	Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation		Alzheimer Disease|Dementia	Drug: galantamine hydrobromide	Phase 3	973	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	July 2002
NCT00253227	A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease		Alzheimer Disease|Dementia	Drug: galantamine hydrobromide	Phase 3	387	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	December 1998
NCT00216593	Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study		Dementia|Alzheimer Disease	Drug: galantamine hydrobromide	Phase 3	415	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	Sep 07	March 2008
NCT01459016	A Non-drug Methods Study in Participants With Alzheimer's Disease		Alzheimer's Disease	Other: PET scan using florbetapir|Other: MRI Scan	Phase 1	56	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	December 2014	December 2014
NCT00838877	Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aî² Amyloid	PET	Alzheimer's Disease	Drug: radioligand [18F]AZD4694|Drug: radioligand [11C]AZD2184	Phase 1	26	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	null	October 2009
NCT00253201	A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease		Alzheimer Disease|Dementia	Drug: galantamine hydrobromide	Phase 3	636	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	October 1997
NCT00253188	A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease		Alzheimer Disease|Dementia	Drug: galantamine hydrobromide	Phase 3	653	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	December 1998
NCT00766363	Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease		Alzheimer's Disease|Central Nervous System Diseases	Drug: EVP-6124 (0.1 mg/day)|Drug: EVP-6124 (0.3 mg/day)|Drug: EVP-6124 (1.0 mg/day)|Drug: Comparator: Placebo|Drug: Donepezil|Drug: Rivastigmine	Phase 1	49	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	March 2009	March 2009
NCT02142777	S-Equol in Alzheimer's Disease (SEAD) Trial	SEAD	Alzheimer's Disease	Drug: S -Equol|Drug: Placebo	Phase 1	15	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Apr 16	Apr 16

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT00702780	Progression Delaying Effect of Escitalopram in Alzheimer's Disease	ESAD	Alzheimer's Disease	Drug: escitalopram|Drug: placebo	Not Applicat	74	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 11	Sep 11
NCT00692705	Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for Î² Amyloid	PET	AlzheimerÂ´s Disease	Drug: Radioligand (11C)AZD2995|Drug: Radioligand (11C)AZD2184	Phase 1	13	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	December 2008	December 2008
NCT01565382	Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)		Alzheimer's Disease	Drug: florbetapir F 18	Not Applicat	40	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	February 2011	February 2011
NCT01249196	A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease		Alzheimer's Disease	Drug: SK-PC-B70M	Phase 3	256	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Aug 13	null
NCT00476008	Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease		Alzheimer's Disease	Drug: Memantine|Drug: Placebo	Phase 4	60	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	October 2012	October 2012
NCT00982202	Pioglitazone in Alzheimer Disease		Alzheimer Disease	Drug: pioglitazone|Drug: Placebo	Phase 2	25	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2005	January 2005
NCT00940589	Efficacy of CircadinÂ® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor		Alzheimer's Disease|Sleep Disorder	Drug: Circadin|Drug: Placebo	Phase 2	73	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	February 2013	May 2013
NCT01023685	To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients		Alzheimer Disease	Biological: CAD106	Phase 2	24	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	February 2012	February 2012
NCT01404169	A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease		Alzheimer's Type Dementia	Drug: E2020|Drug: Placebo	Phase 3	260	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2014	Sep 14
NCT00663026	Study Evaluating Bapineuzumab In Alzheimer Disease Subjects		Alzheimer Disease	Drug: bapineuzumab|Drug: placebo	Phase 2	79	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	October 2010	October 2010
NCT01539031	Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease		Alzheimer's Type Dementia	Drug: E2020	Phase 3	351	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2015	March 2015
NCT00956410	To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients		Alzheimer Disease	Biological: CAD106	Phase 2	21	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	June 2011	June 2011
NCT00800709	Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease		Alzheimer's Disease	Drug: Memantine	Phase 4	26	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	October 2010	October 2010
NCT01703702	Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline		Alzheimer's Disease	Drug: florbetapir (18F)	Phase 4	641	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Apr 15	Apr 15
NCT00726726	Drug Interaction Study With a Potential Alzheimer's Disease Compound		Alzheimer Disease	Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Drug: BMS-708163|Drug: BMS-708163 + Cooperstown Cocktail	Phase 1	22	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	October 2008	October 2008
NCT00153010	An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type		Alzheimer Disease	Drug: NS 2330 (Tesofensine)	Phase 2	430	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	March 2005	null
NCT00024531	Lipitor as a Treatment for Alzheimer's Disease		Alzheimer Disease	Drug: Atorvastatin calcium	Phase 2	98	Interventional	Allocation: Randomized|Masking: Double|Primary Purpose: Treatment	null	Aug 04
NCT00621010	Safety Study of CTS21166 to Treat Alzheimer Disease	CTS	Alzheimer's Disease	Drug: CTS21166 (ZPQ-21166)	Phase 1	56	Interventional	Primary Purpose: Treatment	February 2008	February 2008
NCT00104013	Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type		Alzheimer Disease	Drug: xaliproden (SR57746A)	Phase 3	1455	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	Nov 07	Nov 07
NCT00733863	Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.		Alzheimer Disease	Biological: Placebo|Biological: CAD106	Phase 2	27	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	February 2010	null
NCT00702143	A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)		Alzheimer's Disease|Mild Cognitive Impairment	Drug: florbetapir F 18	Phase 2	184	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	December 2008	December 2008
NCT00795418	Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients		Alzheimer's Disease	Biological: Placebo|Biological: CAD106	Phase 2	31	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Nov 10	null
NCT00103649	18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type		Alzheimer Disease	Drug: xaliproden (SR57746A)	Phase 3	1306	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	October 2007	October 2007

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT01245530	An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia		Alzheimer Type Dementia	Drug: Aricept|Drug: INM-176	Phase 3	280	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	February 2011	March 2011
NCT01097096	Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients		Alzheimer's Disease	Biological: CAD106	Phase 2	177	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2012	December 2012
NCT02016560	Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects		Alzheimer's Disease	Drug: florbetapir F 18|Drug: 18F-AV-1451	Phase 2|Pha	383	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose:	July 28, 2017	July 28, 2017
NCT00531804	A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.		Alzheimer's Disease	Drug: gantenerumab	Phase 1	60	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Sep 10	Sep 10
NCT00322153	A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease		Dementia of the Alzheimer's Type	Drug: memantine ER|Drug: Placebo	Phase 3	677	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	October 2007	January 2008
NCT00777608	A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)		Alzheimer's Disease	Drug: Comparator: Placebo 5mg (run in)|Drug: Donepezil 5 - 10 mg|Drug: Comparator: Placebo 5-10 mg|Drug: Donepezil 10 mg	Phase 1	106	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	October 2009	Apr 10
NCT01565356	Evaluation of PET Scan Timing Relative to AV-45 Injection Time		Alzheimer's Disease	Drug: florbetapir F 18	Not Applicat	41	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	May 2010	May 2010
NCT01741194	AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext	NOURISH-AD	Alzheimer's Disease	Drug: AC-1204|Drug: Placebo	Phase 2|Pha	418	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	October 24, 2016	April 14, 2017
NCT00041678	Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type		Alzheimer Disease	Drug: aripiprazole	Phase 3	null	Interventional	Primary Purpose: Treatment	March 2003	March 2003
NCT00551161	Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease		Alzheimer Disease	Drug: memantine	Phase 4	12	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2011	December 2011
NCT01035138	A Study of Semagacestat for Alzheimer's Patients	Identity XT	Alzheimer's Disease	Drug: semagacestat	Phase 3	180	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Apr 11	Apr 11
NCT00036114	Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type		Alzheimer Disease	Drug: aripiprazole	Phase 3	null	Interventional	Primary Purpose: Treatment	Aug 03	Aug 03
NCT01309763	Safety and Tolerability of AFFITOPE AD03	MimoVax	Alzheimer's Disease	Biological: AFFITOPE AD03|Biological: AFFITOPE AD03 + Alum	Phase 1	28	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Sep 11	Nov 11
NCT00933608	Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease		Alzheimer's Disease	Drug: memantine|Drug: Placebo	Phase 4	17	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	Sep 11	Sep 11
NCT01266525	Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil		Dementia Alzheimer's Type	Drug: SAR110894|Drug: placebo (for SAR110894)|Drug: Donepezil	Phase 2	291	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2013	January 2013
NCT00479219	Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients		Alzheimer Disease	Drug: GSI-953|Other: Placebo	Phase 1	17	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose:	October 2007	October 2007
NCT00988624	A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)		Alzheimer's Disease|Huntington Disease	Drug: Dimebon IR Tablet|Drug: Dimebon MR1|Drug: Dimebon MR2|Drug: Dimebon MR3|Drug: Dimebon MR4	Phase 1	20	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)	December 2009	December 2009
NCT00499200	Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy		Alzheimer's Disease	Drug: SRA-444	Phase 1	42	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose:	June 2008	June 2008
NCT01585272	Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia		Alzheimer's Dementia	Drug: ENA713	Phase 4	121	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	June 2015	June 2015
NCT00401167	Memantine for Agitation and Aggression in Severe Alzheimer's Disease		Alzheimer's Disease	Drug: memantine	Phase 4	32	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	January 2010	January 2010
NCT00151502	To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.		Alzheimer's Disease	Drug: Atorvastatin	Phase 3	600	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	July 2007
NCT01890343	Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.		Alzheimer's Disease|Alzheimer's Disease|Frontotemporal Dementia	Drug: florbetapir 18F|Drug: 18F-FDG	Phase 2	34	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	December 2012	Apr 13
NCT01148498	A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's		Alzheimer's Disease	Drug: solanezumab	Phase 2	55	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	Aug 12	Aug 12
NCT01297218	The Safety and The Efficacy Evaluation of NEUROSTEMÂ®-AD in Patients With Alzheimer's Disease		Dementia of the Alzheimer's Type	Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells	Phase 1	9	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sep 11	December 2011
NCT00141661	A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients		Alzheimer Disease	Drug: PF-04494700 - Low Dose Arm|Drug: PF-04494700 - High Dose Arm|Drug: Placebo Comparator	Phase 2	67	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	June 2006	June 2006
NCT01702467	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers		Alzheimer's Disease	Drug: GSK2647544|Drug: Placebo	Phase 1	27	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	May 15, 2013	May 15, 2013
NCT01467726	Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects		Alzheimer's Disease	Drug: Velusetrag|Drug: Placebo	Phase 1	40	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	January 2012	January 2012

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT02323334	A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease		Healthy Volunteers|Alzheimer Disease	Drug: LY3202626|Drug: Placebo (Part A, B, C)|Drug: Itraconazole	Phase 1	136	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	February 2016	February 2016
NCT01023867	Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia		Alzheimer's Disease|Dementia	Drug: donepezil	Not Applicat	88	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	June 2010	June 2010
NCT02549196	A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type	CPC-12	Dementia of Alzheimer's Type	Drug: CPC-201	Phase 2	28	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	September 28, 201	September 28, 2017
NCT01276353	A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia		Alzheimer's Type Dementia	Drug: E2020	Phase 2	45	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Apr 12	Apr 12
NCT00403520	Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers		Alzheimer's Disease	Drug: Experimental 1|Drug: Placebo Comparator	Phase 4	240	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	March 2008	Aug 10
NCT00901498	Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease		Alzheimer's Disease|Healthy	Drug: BMS-708163	Phase 1	36	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)	July 2009	July 2009
NCT02434666	Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07		Dementia of the Alzheimer's Type	Drug: CPC-201	Phase 2	21	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	October 18, 2016	November 22, 2016
NCT00392912	Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone		Alzheimer's Disease|Hypogonadism	Drug: AndroGel (Solvay Pharmaceuticals)	Not Applicat	10	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Nov 09	July 2010
NCT02576639	Dose-ranging Safety and Tolerability Study in Subjects â‰¥60 Years of Age		Alzheimer's Disease	Drug: CNP520|Drug: Placebo	Phase 2	124	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic	March 11, 2016	March 11, 2016
NCT01020838	Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral Î²-amyloid Compared to Histopathology		Alzheimer Disease	Drug: Florbetaben (BAY94-9172)	Phase 3	218	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Sep 11	December 2013
NCT00991419	To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden		Alzheimer's Disease	Drug: [18F]AZD4694	Phase 2	25	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Aug 11	Aug 11
NCT00689559	Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects		Alzheimer's Disease	Drug: AZD3480|Drug: Placebo|Drug: Aripiprazole	Phase 1	52	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	null	Apr 09
NCT00468897	A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.		Alzheimer's Disease	Drug: RSG XR	Phase 1	50	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	May 2, 2007	May 2, 2007
NCT02874820	I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD	I2PETPG	Alzheimer Disease	Radiation: [11C]BU99008|Drug: Idazoxan	Early Phase	2	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	March 2017	July 2017
NCT00814346	Effect of EGb761Â® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions		Alzheimer's Disease|Cognitive Impairment	Drug: EGb761Â®|Drug: Placebo	Phase 2	49	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	July 2012	July 2012
NCT02553928	Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and Mini Mental State Examination (MMSE)Range 5 - 18		Alzheimer Dementia (AD)	Drug: Memantine (once daily)|Drug: Memantine (twice daily)	Phase 4	62	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	July 2016	July 2016
NCT01825330	Effect of NeuroAD on the Cognitive Function of Alzheimer Patients		Alzheimer's Disease	Device: TMS and cognitive stimulation|Device: sham	Not Applicat	131	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2016	March 2016
NCT01825317	Effect of NeuroAD on Alzheimer Patients		Alzheimer's Disease	Device: NeuroAD|Device: Sham device	Not Applicat	32	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose:	December 2013	December 2013
NCT01548287	A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment		Mild Cognitive Impairment|Mild Alzheimer's Disease	Drug: AZD5213|Other: Placebo	Phase 2	164	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	January 2013	January 2013
NCT00000174	Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)		Alzheimer Disease|Cognition Disorders	Drug: Rivastigmine	Phase 3	null	Interventional	Allocation: Randomized|Masking: Double|Primary Purpose: Treatment	null	null
NCT02681172	Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD		Alzheimer's Disease (AD)	Drug: Neuraceq (florbetaben 18F)|Procedure: PET	Phase 4	218	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	Sep 16	Nov 16
NCT00235716	A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	TEAM-AD	Alzheimer's Disease	Drug: dl-alpha-tocopherol|Drug: Memantine|Drug: Placebo	Phase 3	613	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 12	October 2012
NCT00034762	Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease		Dementia|Alzheimer Disease|Mental Disorders	Drug: risperidone	Phase 3	473	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	January 2003
NCT00750529	Alzheimer and Sleep		Alzheimer's Disease	Drug: Galantamine and Donepezil	Phase 1	15	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sep 13	Sep 13
NCT02256306	The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study	PLASMA	Mild-To-Moderate Alzheimer's Disease|Alzheimer's Disease	Other: Plasma	Not Applicat	18	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	February 2017	February 2017

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT02562989	[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)		Alzheimer's Disease|Amnestic Mild Cognitive Impairment	Drug: [18F]MK-6240, ~185 MBq|Drug: [18F]MK-6240, ~160 MBq	Phase 1	13	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	December 27, 201	December 27, 2016
NCT03587376	Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)		Alzheimer Disease	Drug: Atabecestat	Early Phase	9	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	August 23, 2018	August 23, 2018
NCT01795339	A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients		Healthy Elderly Volunteers|Mild-to-moderate Alzheimer's Disease Patients	Drug: AZD3293|Drug: Placebo	Phase 1	47	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	March 2014	March 2014
NCT03432195	A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplexâ„¢ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations		Alzheimer's Disease	Drug: Donepezil TDS	Phase 1	66	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	June 28, 2018	June 28, 2018
NCT03259958	A Bioequivalence Study of Corplexâ„¢ Donepezil Transdermal Delivery System Compared to AriceptÂ®		Alzheimer's Disease	Drug: Donepezil TDS|Drug: Aricept	Phase 1	86	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	March 13, 2018	March 14, 2018
NCT02968719	A Phase 1, Corplexâ„¢ Donepezil Transdermal System Compared to Oral AriceptÂ®		Alzheimer Disease	Drug: Donepezil TDS Version A|Drug: Donepezil TDS Version B|Drug: Aricept|Drug: Donepezil TDS Version D|Drug: Donepezil TDS Version E	Phase 1	107	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	July 11, 2017	July 11, 2017
NCT00733785	PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers	Rosi XR	Alzheimer's Disease	Drug: Rosiglitazone XR	Phase 1	60	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	November 28, 200	November 28, 2008
NCT01138111	Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients		Alzheimer Disease|Amyloid Beta-Protein	Drug: Florbetaben (BAY94-9172)	Phase 1	45	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	December 2011	December 2011
NCT02840279	A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects		Alzheimer's Disease	Drug: BPN14770|Drug: Placebo	Phase 1	77	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Nov 16	December 2016
NCT02795780	Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05		Alzheimer's Disease	Drug: 18F-AV-1451	Phase 2	79	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	August 28, 2017	August 28, 2017
NCT02782975	Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants		Alzheimer's Disease	Drug: aducanumab	Phase 1	28	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	Nov 16	Nov 16
NCT00954369	Exploratory and Safety Study of [F-18]W372		Alzheimer's Disease	Drug: [F-18]W372	Early Phase	24	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)	February 2010	February 2010
NCT02710188	Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation		Alzheimer's Disease	Drug: HTL0009936 modified release|Drug: HTL0009936 immediate release	Phase 1	14	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	July 2016	Aug 16
NCT02859207	A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects		Early Alzheimer's Disease	Drug: E2609	Phase 1	32	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 6, 2016	January 25, 2017
NCT02648672	BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects		Alzheimer's Disease	Drug: BPN14770|Drug: Placebo	Phase 1	32	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	February 2016	July 2016
NCT00759863	LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia	Lifezig	Alzheimer's Disease|Dementia	Behavioral: Lifezig	Phase 2	242	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Apr 09	Apr 09
NCT02621606	[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)		Alzheimer's Disease	Drug: [11C]MK-6884	Phase 1	20	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	December 28, 201	December 28, 2017
NCT02340195	Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function		Alzheimer Disease	Drug: Idalopirdine (Lu AE58054) 60 mg	Phase 1	16	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sep 15	null
NCT02534480	Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)		Alzheimer's Disease	Drug: NGP 555	Phase 1	40	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	October 2015	Nov 15
NCT02516046	18F-AV-1451 Autopsy Study		Alzheimer's Disease	Drug: 18F-AV-1451	Phase 3	156	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	June 13, 2018	July 15, 2018
NCT02178124	A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.		Alzheimer Disease	Drug: Donepezil|Drug: placebo	Phase 1	24	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	December 2014	December 2014
NCT02336360	Augmenting 18F-AV-1451 Dosimetry Estimates		Alzheimer's Disease	Drug: 18F-AV-1451	Phase 1	6	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	June 2015	June 2015
NCT00366483	Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects		Alzheimer Disease	Drug: Lecozotan SR	Phase 1	40	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	null
NCT02291783	Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment		Alzheimer's Disease	Drug: HTL0009936|Drug: HTL0009936 placebo	Phase 1	108	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2014	July 2014
NCT02278354	Tau Imaging in Professional Fighters		Alzheimer's Disease	Drug: 18F-AV-1451	Phase 1	30	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	February 3, 2017	February 3, 2017
NCT01656525	A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients		Alzheimer's Disease	Drug: Gantenerumab|Drug: Placebo	Phase 1	28	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	March 2014	June 2014

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT02120664	Florbetapir Calibration to the Centiloid Scale		Alzheimer's Disease	Drug: Florbetapir (18F)|Drug: 11C-PiB	Phase 1	35	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose:	Sep 15	Sep 15
NCT02107599	The Feasibility of Florbetapir Quantitation in Europe		Alzheimer's Disease	Drug: Florbetapir (18F)	Phase 4	96	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	May 2014	May 2014
NCT02061878	A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects		Alzheimer's Disease	Drug: Bexarotene|Drug: Placebo	Phase 1	12	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)	Nov 14	Nov 14
NCT02051790	Evaluation of Reader Training Processes		Alzheimer's Disease	Drug: florbetapir F 18	Phase 4	241	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose:	Aug 14	Aug 14
NCT02051764	Imaging Characteristics of a Follow-up 18F-AV-1451 Scan		Alzheimer's Disease	Drug: 18F-AV-1451|Drug: Florbetapir F 18	Phase 2	38	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	December 2016	December 2016
NCT01860625	A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects		Alzheimer Disease	Drug: Donepezil patch|Drug: placebo	Phase 1	36	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	December 2013	February 2014
NCT01946243	The Feasibility of Florbetapir Quantitation		Alzheimers Disease	Drug: Florbetapir F18	Phase 4	96	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	Apr 14	Apr 14
NCT01992380	A Study of 18F-AV-1451 in Healthy Volunteers and Cognitively Impaired Subjects		Alzheimer's Disease	Drug: 18F-AV-1451	Phase 1	24	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose:	May 2014	May 2014
NCT01584440	Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients		Agitation|Alzheimer's Disease	Drug: AVP-923 (dextromethorphan/quinidine)|Drug: Placebo	Phase 2	220	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2014	Sep 14
NCT02423122	A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)		Alzheimer's Disease|Mild Cognitive Impairment	Drug: VX-745	Phase 2	16	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2016	Sep 16
NCT01564706	A Study of 18F-AV-45 in Healthy Volunteers		Alzheimer Disease	Drug: florbetapir F 18	Phase 1	9	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	January 2008	January 2008
NCT01716897	An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption		Alzheimer's Disease	Drug: E2609	Phase 1	18	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2012	February 2013
NCT01230853	A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study		Alzheimer's Disease	Drug: Active Comparator: A|Drug: Placebo Comparator B|Drug: Active Comparator B|Drug: Placebo Comparator A	Phase 1	80	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	October 2012	February 2013
NCT01565369	Evaluation of Physician Training Methods to Read Florbetapir-PET Scans		Alzheimer's Disease	Drug: florbetapir F 18	Not Applicat	35	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	January 2011	January 2011
NCT01454115	Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163		Alzheimer's Disease	Drug: BMS-708163 (Gamma-Secretase Inhibitor)|Drug: Placebo matching BMS-708163	Phase 1	116	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	March 2009	March 2009
NCT01447719	Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07		Alzheimer's Disease	Drug: florbetapir F 18	Phase 3	110	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	March 2011	July 2011
NCT00857506	Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)		Alzheimer's Disease|Mild Cognitive Impairment	Drug: florbetapir F 18	Phase 2	152	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	December 2011	December 2011
NCT01303744	Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074	CT04	Alzheimer's Disease	Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x|Drug: Placebo	Phase 2	96	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Apr 12	Apr 12
NCT01294540	Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort		Alzheimer's Disease	Drug: Drug: E2609|Drug: Placebo	Phase 1	73	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	October 2011	December 2011
NCT01258452	Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects	CT03	Alzheimer's Disease	Drug: CHF 5074|Drug: CHF 5974	Phase 1	12	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	March 2011	March 2011
NCT01253499	Multiple Dose Study of TRx0037		Alzheimer's Disease	Drug: TRx0037	Phase 1	31	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes	May 2010	May 2010
NCT01253122	Comparative Bioavailability in Healthy Elderly Volunteers		Alzheimer's Disease	Drug: TRx0037	Phase 1	24	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	Apr 10	Apr 10
NCT01227252	A Safety Study of LY2886721 Multiple Doses in Healthy Subjects		Alzheimer's Disease	Drug: LY2886721|Drug: Placebo	Phase 1	42	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	Apr 11	Apr 11
NCT01093664	Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02		Alzheimer's Disease	Biological: AFFITOPE AD02	Phase 1	20	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	July 2010	July 2010
NCT01221259	A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects		Alzheimer's Disease	Drug: E2212|Drug: placebo	Phase 1	60	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	October 2011	Nov 12
NCT01057030	Multiple Dose Japanese Bridging Study		Alzheimer Disease	Drug: BMS-708163|Drug: Placebo	Phase 1	22	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)	June 2010	June 2010
NCT01203384	Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects	CT02	Alzheimer's Disease	Drug: CHF5074 1x|Drug: CHF5074 2x|Drug: CHF5074 3x|Drug: Placebo	Phase 1	48	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2010	December 2010

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT01042314	Drug-Drug Interaction Study With AriceptÂ® (Donepezil)		Alzheimer Disease	Drug: Donepezil|Drug: BMS-708163	Phase 1	18	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)	Apr 10	Apr 10
NCT01039194	Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)		Alzheimer Disease	Drug: galantamine|Drug: BMS-708163	Phase 1	18	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)	Apr 10	Apr 10
NCT01133405	A Safety Study of LY2886721 Single Doses in Healthy Subjects		Alzheimer's Disease	Drug: LY2886721|Drug: Placebo	Phase 1	0	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	October 2010	October 2010
NCT00979316	Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects		Alzheimer Disease	Drug: BMS-708163|Drug: Placebo|Drug: Moxifloxacin	Phase 1	62	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)	February 2010	February 2010
NCT01079819	Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163		Alzheimer's Disease	Drug: BMS-708163|Drug: Placebo	Phase 1	32	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	December 2010	December 2010
NCT00906191	Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects		Alzheimer Disease	Drug: SAM-531	Phase 1	6	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	Aug 09	Aug 09
NCT00860275	Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole		Alzheimer Disease	Drug: BMS-708163|Drug: BMS-708163 + Ketoconazole|Drug: Ketoconazole|Drug: Fluconazole|Drug: BMS-708163 + Fluconazole	Phase 1	30	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	June 2009	June 2009
NCT00719394	Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males		Alzheimer Disease|Healthy	Drug: GSI 136|Drug: placebo	Phase 1	72	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose:	Aug 08	Aug 08
NCT00718731	Study GSI-136 in Healthy Young and Healthy Elderly Subjects		Alzheimer Disease|Healthy	Drug: GSI-136|Other: Placebo	Phase 1	80	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Aug 08	Aug 08
NCT00954538	Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)		Alzheimer's Disease	Drug: [18F]MK-3328	Phase 1	19	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	May 2011	May 2011
NCT00954252	Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects	CT01	Alzheimer's Disease	Drug: CHF 5074|Drug: placebo	Phase 1	84	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)	May 2010	May 2010
NCT00684710	Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects		Alzheimer Disease|Healthy	Drug: PAZ-417|Drug: Placebo	Phase 1	56	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose:	Aug 08	Aug 08
NCT00765115	A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.		Alzheimer Disease	Drug: LY450139|Drug: placebo	Phase 1	27	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)	Sep 07	Sep 07
NCT00745576	Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered		Alzheimer Disease	Drug: SAM-531	Phase 1	14	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2008	December 2008
NCT00726115	Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531		Alzheimer Disease	Drug: SAM-531|Drug: placebo	Phase 1	56	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	February 2009	February 2009
NCT00867399	A Safety and Tolerability Study of ABT-126 in Elderly		Alzheimer's Disease	Drug: ABT-126	Phase 1	30	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose:	May 2009	null
NCT00838084	A Safety Study of LY2811376 Single Doses in Healthy Subjects		Alzheimer's Disease	Drug: LY2811376|Drug: Placebo	Phase 1	61	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	June 2009	June 2009
NCT00563732	Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin		Alzheimer Disease	Drug: Lecozotan	Phase 1	null	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sep 08	Sep 08
NCT00990613	A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin		Alzheimer's Disease|Huntington's Disease	Drug: Dimebon IR|Drug: Dimebon Transdermal	Phase 1	19	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)	January 2010	January 2010
NCT00689637	Drug Interaction Study Between AZD3480 and Warfarin	DDI	Alzheimer's Disease	Drug: AZD3480|Drug: Placebo|Drug: Warfarin	Phase 1	26	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	null	February 2009
NCT00687141	Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects		Alzheimer's Disease	Drug: AZD0328|Drug: Placebo	Phase 1	112	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	June 2008	June 2008
NCT00831506	Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects		Alzheimer Disease|Huntington Disease	Drug: digoxin|Drug: dimebon	Phase 1	12	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2009	May 2009
NCT00975481	A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepiridine) In Healthy Recreational Polydrug Users		Alzheimer's Disease|Huntington's Disease	Drug: dimebon|Drug: placebo|Drug: alprazolam	Phase 1	36	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)	February 2010	February 2010
NCT00105547	Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's		Alzheimer Disease|Dementia	Drug: MPC-7869	Phase 3	1600	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	null	May 2008
NCT00931073	A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers		Alzheimer's Disease|Huntington's Disease	Drug: Dimebon alone|Drug: Dimebon + Ketoconazole|Drug: Dimebon + Omeprazole	Phase 1	24	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)	October 2009	October 2009
NCT00624026	Memantine - Communication Study		Alzheimer's Disease	Drug: Memantine-HCl	Phase 3	107	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2008	December 2008
NCT00494962	Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects		Alzheimer Disease	Drug: lecozotan SR	Phase 1	40	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	null	June 2007
NCT00480818	Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects		Alzheimer Disease	Drug: SAM-531	Phase 1	80	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	null	July 2007

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT00480467	Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males		Alzheimer Disease	Drug: SAM-315	Phase 1	32	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	null	Aug 07
NCT00479700	Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects		Alzheimer Disease	Drug: SAM-531	Phase 1	80	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	null	July 2006
NCT00479440	Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults		Alzheimer Disease	Drug: SAM-315	Phase 1	56	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	null	March 2007
NCT00479349	Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531		Alzheimer Disease	Drug: SAM-531	Phase 1	32	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose:	January 2008	January 2008
NCT00479297	Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males		Alzheimer Disease	Drug: SAM-531	Phase 1	72	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	February 2007	February 2007
NCT00452504	Single Ascending Dose Study of SRA-444 in Healthy Subjects		Alzheimer Disease	Drug: SRA-444	Phase 1	64	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	null	June 2007
NCT00551772	A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.		Alzheimer's Disease	Drug: SB-742457	Phase 1	12	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	null	null
NCT00827034	A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects		Alzheimer's Disease|Huntington's Disease	Drug: Warfarin|Drug: Dimebon	Phase 1	14	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Apr 09	Apr 09
NCT00825084	A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects		Alzheimer's Disease|Huntington's Disease	Drug: Dimebon	Phase 1	45	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	May 2009	May 2009
NCT00824590	A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function		Alzheimer's Disease|Huntington's Disease	Drug: Dimebon	Phase 1	20	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	October 2009	October 2009
NCT00483028	A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI		Alzheimer's Disease	Drug: donezepil (Aricept)	Not Applicat	38	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	January 2007
NCT00165659	A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020		Alzheimer Disease Huntington	Drug: DONEPEZIL HYDROCHLORIDE	Phase 2	null	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	May 2005	null
NCT00788047	A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan		Disease|Alzheimer Disease	Drug: Dextromethorphan|Drug: Dimebon + Dextromethorphan	Phase 1	14	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	January 2009	January 2009
NCT00236574	A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment		Dementia|Alzheimer Disease	Drug: Galantamine hydrobromide	Phase 3	974	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	Nov 03
NCT01325402	An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease		Maximum Diagnostic Mass of [18Fluor]AZD4694	Other: [18Fluor]AZD4694	Phase 1	16	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	Nov 12	Nov 12
NCT01354691	Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease		Alzheimer's Disease|Dementia|Memory Loss|Cognitive Impairment	Drug: ladostigil hemitartrate	Phase 2	201	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 12	March 2013
NCT01153607	Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers		Diagnostic Imaging	Drug: BAY1006578	Phase 1	24	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	October 2011	October 2011
NCT02078310	Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia		Alzheimer's Disease	Drug: ITI-007|Drug: Placebo	Phase 1|Pha	35	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	Aug 14	Nov 14
NCT00095719	Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia		Dementia|Alzheimer's Disease	Drug: Aripiprazole|Drug: Placebo	Phase 3	125	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	March 2005	March 2005
NCT01504958	Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients		Alzheimer's Disease	Device: Repetitive Transcranial Magnetic Stimulation (rTMS)|Behavioral: NICE Cognitive Training	Not Applicat	22	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	May 2015	May 2015
NCT01009359	Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers		Diagnostic Imaging	Drug: F-18 DPA-714 (BAY85-8102)	Phase 1	22	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	July 2010	October 2010
NCT01702480	Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects		Alzheimer's Disease	Drug: GSK2981710|Drug: Placebo	Phase 1	116	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	July 3, 2015	July 3, 2015
NCT01602393	Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase	CT04 POLEP	Alzheimer's Disease	Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x	Phase 2	51	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	October 2013	October 2013

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT01537757	A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])		Alzheimer's Disease	Drug: MK-8931	Phase 1	12	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	May 2012	May 2012
NCT01421056	Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)		Alzheimer's Disease	Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x	Phase 2	74	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Nov 12	Nov 12
NCT02331784	Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease	PACR-AD	Older Adults, Aging Brain	Behavioral: Computerized Plasticity-based Software|Behavioral: Commercially available Video Game	Not Applicat	68	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science	April 20, 2017	April 20, 2017
NCT02273895	The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study		AD	Drug: Scopolamine	Not Applicat	29	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	October 2004	January 2010
NCT00857415	Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain		Alzheimer's Disease	Drug: florbetapir F 18	Phase 3	226	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose:	March 2010	May 2010
NCT00236431	A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment		Dementia|Alzheimer Disease	Drug: Galantamine hydrobromide	Phase 3	1063	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	December 2003
NCT00441987	Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953		Alzheimer Disease|Healthy	Drug: GSI-953	Phase 1	96	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose:	July 2009	July 2009
NCT03611439	Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients		Alzheimer Disease|Alzheimer Dementia	Dietary Supplement: ReBuilder|Dietary Supplement: Placebo	Not Applicat	50	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 25, 201	December 25, 2015
NCT01922258	Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type		Agitation Associated With|Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases	Drug: Brexpiprazole, OPC-34712	Phase 3	270	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	March 2017	March 2017
NCT01862640	Safety and Tolerability Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type		Agitation Associated With|Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases	Drug: Brexpiprazole, OPC-34712	Phase 3	433	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	March 2017	March 2017
NCT02813070	Comparison of PET Amyloid Imaging in Japanese and Western Subjects		Mild Cognitive Impairment|Alzheimer's Disease|Healthy	Drug: [18F] Flutemetamol	Phase 2	70	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	May 2013	May 2013
NCT00325728	Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease		Chronic Insomnia	Drug: Ramelteon|Drug: Placebo	Phase 2	74	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	August 1, 2007	August 20, 2007
NCT01168245	TMS Stimulation and Cognitive Training in Alzheimer Patients		Alzheimer Disease|Mild to Moderate	Device: Sham-NICE-System|Device: NICE-System	Phase 1	15	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Sep 11	Sep 11
NCT01068353	Safety and Tolerability of Etanercept in Alzheimer's Disease	STEADI-09	Alzheimer's Disease	Biological: Etanercept|Other: Placebo	Phase 2	41	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2013	null
NCT01297036	Pharmacokinetic Comparisons of Two Donepezil Formulations		Alzheimer Disease	Drug: Donepezil, ODT 10 mg|Drug: Donepezil, 10 mg tablet	Phase 1	22	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)	March 2008	May 2008
NCT00120874	Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training		Alzheimer's Disease	Behavioral: Individualized management of AD including caregiver training|Drug: Memantine	Phase 4	20	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)	Nov 11	Nov 11
NCT01438060	Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type		Dementia, Alzheimer Type	Drug: Aripiprazole (BMS-337039)|Drug: Placebo	Phase 3	232	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2010	July 2010
NCT01672827	Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images		Alzheimer's Disease|Mild Cognitive Impairment	Drug: [18F]Flutemetamol	Phase 3	276	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	Aug 12	Aug 12
NCT00299988	Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease		Alzheimer's Disease	Drug: Intravenous Immunoglobulin	Phase 2	24	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	January 2009	Apr 10
NCT02370524	Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease		Alzheimer's Disease (AD)	Drug: [18F]T807	Phase 1	16	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	January 2016	January 2016
NCT02051335	Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults		Memory Impairment|Alzheimer's Disease	Drug: Roflumilast|Drug: Roflumilast placebo|Drug: Donepezil|Drug: Donepezil placebo|Drug: Scopolamine	Phase 1	27	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2014	May 2014

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT00440050	DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease	DHA	Alzheimer's Disease	Drug: DHA (Docosahexaenoic Acid)|Drug: Placebo	Phase 3	402	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	May 2009	May 2009
NCT00255086	The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients		Alzheimer Disease	Drug: Memantine|Drug: Placebo pill	Phase 3	17	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	June 2009	February 2010
NCT02910102	Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia		Alzheimer's Disease|Dementia With Lewy Bodies|Parkinson's Disease Dementia	Drug: RVT-101 35 mg|Drug: Placebo	Phase 2	38	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Nov 17	Nov 17
NCT00499642	Study Evaluating the Effect of Lecozotan SR on the QTc Interval		Alzheimer Disease|Healthy	Drug: Lecozotan SR|Drug: Moxifloxacin	Phase 1	null	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment	null	Aug 07
NCT01172145	Treatment of Apathy in Alzheimer's Disease With Modafinil		Apathy|Alzheimer's Disease	Drug: Modafinil|Drug: Placebo	Phase 3	22	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose:	null	Sep 07
NCT00692510	Drug Interaction Study Between AZD3480 and Cytochrome P450	Cocktail	Metabolism|Alzheimer's Disease	Drug: AZD3480|Drug: Placebo|Drug: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)	Phase 1	18	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	Sep 08	Sep 08
NCT02489110	Webnovela for Hispanic Dementia Family Caregivers		Alzheimer's Disease|Dementia	Behavioral: Webnovela|Behavioral: Information	Not Applicat	150	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	May 2016	Sep 16
NCT01378195	iCare Stress Management e-Training for Dementia Family Caregivers	iCare	Alzheimer's Disease|Dementia	Behavioral: CBT-based program for dementia caregivers|Behavioral: Educational/Resources program	Phase 2	150	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	July 2012	July 2012
NCT00083590	Huperzine A in Alzheimer's Disease		Alzheimer Disease	Drug: Huperzine A	Phase 2	150	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	Nov 07	Nov 07
NCT00479843	Nutritional Programme for Dementia Elderly Patient		Alzheimer's Disease|Dementia	Behavioral: Nutritional programme	Not Applicat	946	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	July 2007	July 2007
NCT00261573	A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia		Alzheimer Disease|Vascular Dementia	Drug: galantamine hydrobromide	Phase 3	593	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	December 2000
NCT00470418	Development of NIC5-15 in the Treatment of Alzheimer's Disease		Alzheimer Disease|Dementia	Drug: NIC5-15|Drug: Placebo	Phase 2	15	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Aug 08	March 2010
NCT01503944	A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)		Dementia With Lewy Bodies|Alzheimer's Disease|Parkinson's Disease	Drug: 18F-AV-133|Drug: 18F-AV-45	Phase 1|Pha	30	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	July 2011	July 2011
NCT00515333	TRx0014 in Patients With Mild or Moderate Alzheimer's Disease		Dementia, Alzheimer Type	Drug: TRx0014|Drug: Placebo	Phase 2	323	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2007	December 2007
NCT02309723	Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.		Alzheimer's Disease|Mild Cognitive Impairment	Device: Beta amyloid imaging	Not Applicat	315	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Sep 13	Nov 13
NCT00006399	Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease		Alzheimer Disease	Drug: Donepezil|Drug: Estrogen|Drug: Progesterone	Phase 2	45	Interventional	Masking: Double|Primary Purpose: Treatment	March 2004	March 2004
NCT02210286	Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia		Dementia|Alzheimer's Disease	Dietary Supplement: Magtein	Not Applicat	20	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Apr 16	July 2016
NCT00396825	Video-Based Coping Skills Training for Caregivers		Caregivers	Behavioral: Video-based coping skills training with telephone coaching	Phase 2	116	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	May 2009	May 2009
NCT00216502	A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease		Alzheimer Disease|Dementia|Mental Disorders|Brain Diseases	Drug: galantamine hydrobromide	Phase 3	254	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	Nov 05
NCT00260624	Escitalopram Treatment of Patients With Agitated Dementia		Alzheimer's Disease|Psychomotor Agitation	Drug: Escitalopram (Lexapro)	Phase 4	20	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2006	December 2006
NCT00621647	Seroquel- Agitation Associated With Dementia		Alzheimer's Disease|Vascular Dementia	Drug: Quetiapine Fumarate|Drug: Placebo	Phase 3	333	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Nov 03	Nov 03
NCT01652222	Experimental Study to Validate the "Therapeutic Game" CONEM-BETA		Alzheimer's Disease|Dementia	Other: CONEM-BETA + socio-educational training|Other: Socio-educational training only	Not Applicat	101	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	July 2012	Aug 12

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT02910739	An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)		Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease	Drug: MK-8931	Phase 1	16	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	April 3, 2017	April 12, 2017
NCT01023425	Clinical Trial of Donepezil Between the Naive Group and the Switching Group		Alzheimer's Disease|Dementia	Drug: donepezil	Not Applicat	72	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Apr 09	Apr 09
NCT02323217	I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers	I2PETHV	Healthy Volunteers|Alzheimer Disease|Molecular Imaging	Radiation: [11C]BU99008|Drug: Idazoxan|Drug: Isocarboxazid	Early Phase	20	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	February 2016	July 2016
NCT02531360	Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies		Alzheimer's Disease (AD)|Progressive Supranuclear Palsy (PSP)|Cortical Basal Syndrome (CBS)|Frontal Temporal Dementia (FTD)	Drug: [18F]MNI-815 (MNI-815)	Early Phase	7	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)	July 2016	Aug 16
NCT00249158	A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia		Dementia|Alzheimer Disease|Vascular Dementia	Drug: Risperidone	Phase 3	344	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	February 2001
NCT01550549	Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans		Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases	Drug: florbetapir F 18	Not Applicat	151	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	Sep 11	Sep 11
NCT01518374	Clinical Evaluation of Florbetapir F 18 (18F-AV-45)		Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases	Drug: Florbetapir F 18	Phase 2	1768	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	May 3, 2017	May 3, 2017
NCT00249145	A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia		Dementia|Alzheimer Disease|Dementia, Vascular	Drug: risperidone	Phase 3	349	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	December 1996
NCT00276510	A Study of EGb 761Â® (TanakanÂ®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints		Memory Disorders, Age-Related|Retention Disorders, Cognitive	Drug: EGb 761Â® (TanakanÂ®)|Other: Placebo	Phase 4	2878	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Nov 09	Nov 09
NCT01348737	Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers		Alzheimer's Disease|Safety|Tolerability|Blood Concentration|Healthy Volunteers	Drug: AZD3839|Drug: AZD3839 Placebo	Phase 1	72	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	Nov 11	Nov 11
NCT00253123	A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia		Dementia|Alzheimer Disease|Dementia, Vascular	Drug: risperidone	Phase 3	626	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	null	March 1997
NCT01029132	Characteristics of Treatment Responders to Galantamine		Dementia	Drug: galantamine	Not Applicat	66	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	October 2009	October 2009
NCT00539305	Hormone and Information Processing Study	HIP	Mild Cognitive Impairment|Alzheimer's Disease	Drug: testosterone gel|Drug: placebo gel	Phase 3	22	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2011	May 2012
NCT00208819	A Comparison of Two Standard Therapies in the Management of Dementia With Agitation		Senile Dementia, Alzheimer Type|Dementia, Alzheimer Type|Alzheimer Disease|Dementia	Drug: risperidone|Drug: quetiapine|Drug: olanzapine|Drug: divalproex	Phase 4	50	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	null	July 2007
NCT01153802	An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands		Depressive Disorder	Drug: GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin	Phase 1	12	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	October 12, 2009	October 12, 2009
NCT00056524	Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)		Alzheimer's Disease|Stroke|Parkinson's Disease|Traumatic Brain Injury	Drug: AVP-923	Phase 3	600	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	June 2007	June 2007

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT00209456	Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia		Lewy Body Dementia|Non-DLB Dementia|Alzheimerâ€™s|Vascular Dementia	Drug: DatSCAN	Phase 3	326	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	null	null
NCT00814502	Zolpidem CR and Hospitalized Patients With Dementia		Dementia|Alzheimer Disease|Dementia, Vascular|Sleep Disorders|Circadian Dysregulation	Drug: Zolpidem CR|Drug: Placebo	Not Applicat	20	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2013	December 2013
NCT00597376	Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints		Subjective Memory Loss in Older Persons	Other: Cerefolin NAC (a medical food)|Other: Cerefolin NAC placebo	Not Applicat	104	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	May 2011	May 2011
NCT00966966	Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered		Healthy	Drug: SAM-531 and gemfibrozil	Phase 1	17	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2009	December 2009
NCT00959881	Study Evaluating The Coadministration of Begacestat And Donepezil		Healthy Subjects	Drug: Donepezil plus placebo|Drug: Donepezil|Drug: Begacestat	Phase 1	47	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	Nov 09	Nov 09
NCT00547560	Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population		Healthy	Drug: GSI-953	Phase 1	49	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose:	October 2009	October 2009
NCT00145132	Beta-CIT-SPECT and Neurophysiology in Depression		Depression	Procedure: Î²-CIT-SPECT, Neurophysiology	Phase 4	30	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	December 2009	December 2009
NCT02509117	First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979		Healthy Subjects	Drug: PF-06751979 single ascending dose|Drug: Placebo single dose|Drug: PF-06751979 multiple ascending dose|Drug: Placebo multiple dose|Drug: PF-06751979 multiple dose	Phase 1	55	Interventional	Allocation: Randomized|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science	July 2016	July 2016
NCT00519298	Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects		Healthy|Adult	Drug: SAM-531|Other: placebo|Drug: Donepezil	Phase 1	25	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)	March 2008	March 2008
NCT02550665	Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg	ODESA	Alzheimer's Disease	Drug: donepezil	Phase 3	176	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Aug 16	October 2016
NCT02017340	A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease	NILVAD	Alzheimer's Disease	Drug: Nilvadipine|Drug: Placebo	Phase 3	511	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 16, 201	December 16, 2016
NCT02570997	Ascending Dose Study of CT1812 in Healthy Volunteers		Cognitive Impairment	Drug: CT1812|Drug: Placebo	Phase 1	80	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	May 2016	null
NCT02126514	A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293	AZD3293hADME	Healthy Volunteers|Mass Balance Study	Drug: AZD3293	Phase 1	12	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	May 2014	May 2014
NCT00486044	Evaluating Simvastatin's Potential Role in Therapy	ESPRIT	Alzheimer Disease	Drug: Simvastatin|Drug: Placebo	Phase 2	103	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose:	June 2009	June 2009
NCT00855686	Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies		Parkinson's Disease Dementia|Dementia With Lewy Bodies	Drug: Memantine|Drug: Placebo	Phase 4	199	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	December 2008	January 2009
NCT02180269	A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants		Healthy	Drug: JNJ-54861911 (25 mg)|Drug: JNJ-54861911 (50 mg)|Drug: JNJ-54861911 (100 mg)|Drug: Placebo	Phase 1	24	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Aug 14	Aug 14
NCT00545974	Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia		Frontal Lobe Dementia|Frontotemporal Lobe Dementia|Semantic Dementia	Drug: memantine|Drug: Placebo pill	Phase 4	81	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	December 2012	December 2012
NCT00937846	Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study		Cognitive Disorders	Drug: GSK1034702	Phase 1	4	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	August 28, 2009	August 28, 2009
NCT02260700	A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants		Healthy	Drug: JNJ-54861911 (Treatment A)|Drug: JNJ-54861911 (Treatment B)|Drug: JNJ-54861911 (Treatment C)	Phase 1	12	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Nov 13	Nov 13
NCT02793232	Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.		Healthy Subjects	Drug: PF-06751979 single dose|Drug: Placebo single dose|Drug: PF-06751979 multiple ascending dose|Drug: Placebo multiple ascending dose|Drug: PF-06751979 multiple dose|Drug: Placebo multiple elderly dose	Phase 1	46	Interventional	Allocation: Randomized|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	January 2017	January 2017

ClinTrial.gov - Industry-sponsored and completed Alzheimer's trials
August 2018

NCT Number	Title	Acronym	Conditions	Interventions	Phases	Enrollment	Study Type	Study Designs	Primary Completion Date	Completion Date
NCT01429623	A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment		Mild Cognitive Impairment|Dementia	Drug: ladostigil hemitartrate|Drug: Placebo	Phase 2	210	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	July 2016	Sep 16
NCT01827982	A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo		Healthy	Drug: JNJ-54861911 1mg|Drug: JNJ-54861911 3 mg|Drug: JNJ-54861911 9 mg|Drug: JNJ-54861911 27 mg|Drug: JNJ-54861911 81 mg|Drug: JNJ-54861911 160 mg|Drug: JNJ-54861911 tbd|Drug: Placebo	Phase 1	56	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	July 2013	July 2013
NCT02197884	A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants		Healthy	Drug: JNJ-54861911, 25 mg|Drug: Itraconazole 200 mg|Drug: Clarithromycin 500 mg	Phase 1	13	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sep 14	Sep 14
NCT00040443	Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.		Mild Cognitive Impairment	Drug: CX516|Drug: Placebo	Phase 2	175	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Aug 03	June 2004
NCT00959803	Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.		Healthy	Drug: PF-04447943|Drug: Placebo	Phase 1	17	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Nov 09	Nov 09
NCT00240695	A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment		Cognition Disorder|Nervous System Diseases|Mental Disorders|Brain Diseases	Drug: galantamine hydrobromide	Phase 3	724	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	null	May 2004
NCT02211079	A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates		Healthy	Drug: JNJ-54861911|Drug: Caffeine|Drug: Midazolam|Drug: Tolbutamide	Phase 1	16	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Nov 14	Nov 14
NCT02005991	A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377		Healthy	Drug: PF-05212377	Phase 1	4	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	January 2014	January 2014
NCT01887535	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants		Healthy	Drug: JNJ-54861911 3 mg|Drug: JNJ-54861911 10 mg|Drug: JNJ-54861911 30 mg|Drug: JNJ-54861911 80 mg|Drug: JNJ-54861911 25 mg|Drug: Placebo	Phase 1	70	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	December 2013	December 2013
NCT01688128	Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART)	U-SMART	Mild Cognitive Impairment	Device: Phase I U-SMART (4 wks)|Other: Washout (2 wks)|Device: Phase II U-SMART (4 wks)	Phase 3	50	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	December 2015	December 2015
NCT01628653	Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training	U-SMART	Mild Cognitive Impairment	Device: U-SMART	Phase 1	10	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	February 2012	February 2012

ANNEX II. Overview Clinical Trial Data Platform Sharing

ClinicalStudyDataRequest					
Sponsor	Study Drug	AD patient population	Duration	Number of sujects	Phase
GSK	GSK239512	mild moderate	29 days	28	Phase 1
		mild moderate	16 weeks	196	Phase 2
	GSK933776	mild and MCI	2 months	19	Phase 1
		probable (mild)	52 weeks	50	Phase 1
	Rilapladib	possible (MMSE score between 20 and 26 at Screening)	24 weeks	124	Phase 2
	Rosiglitazone	mild	single dose	14	Phase 1
		mild moderate	open-label extension 1 year	33	Phase 2
		mild moderate	12 months	80	Phase 2
		mild moderate	open-label extension 82 weeks	331	Phase 3
		mild moderate	open-label extension 48 weeks	422	Phase 2
		mild moderate	24 weeks	500	Phase 2
		mild moderate	24 weeks	862	Phase 3
		mild moderate	open-label extension 82 weeks	1461	Phase 3
		mild moderate	54 weeks	1468	Phase 3
		mild moderate	54 weeks	1496	Phase 3
Lilly	Semagacestat	mild moderate	29 weeks	45	Phase 3
		mild moderate	open-label extension 24 months	180	Phase 3
		probable	16 weeks	180	Phase 3
		probable	16 weeks	180	Phase 3
Novartis	Rivastigmine	MCI	48 months	1018	Phase 3
		mild moderate	48 weeks	1584	Phase 3
		probable	24 weeks	1040	Phase 3
		probable (MMSE 10-20)	24 weeks	859	Phase 3
		severe	24 weeks	716	Phase 4

YODA					
Sponsor	Study Drug	AD patient population	Duration	Number of sujects	Phase
Janssen	Galantamine	mild moderate	6 months	469	Phase 3
		mild moderate	9 months	144	Phase 3
		Alzheimer + vascular dementia	2-4 years	33	Phase 3
		Vascular dementia			
		mild moderate	4 months	130	
		mild moderate	5 months	979	Phase 3
		probable MCI	36 months	254	Phase 3
		severe	6 months	407	Phase 3
		MCI	24 months	1062	Phase 3
		MCI	24 months	974	Phase 3
		mild moderate	6 months	653	Phase 3
		mild moderate	6 months	636	Phase 3
		mild moderate	26 weeks	965	Phase 3
		probable mild moderate	3 months	387	Phase 3
		vascular and mixed dementia	7 months	593	Phase 3
		mild moderate	6 months	241	Phase 3
		mild moderate	16 weeks	215	Phase 3
		mild moderate	24 months	2051	Phase 3
		mild moderate	3 months	285	
		mild moderate	12 weeks	83	Phase 3
	Risperidone	MMSE 5-23	8 weeks	473	Phase 3

ANNEX III. Identified data sources in Europe

Database/cohort name	Country	Fingerprint		
		EMIF-AD	EMIF-EHR	DPUK
20-07 The West of Scotland Twenty 07 Study	UK			
3C Study Three-City study	France	Invitation sent		
4C Study	the Netherlands	Invitation sent		
50 linked clinical databases (5.6M)	Denmark			
95+ cohort	Sweden			
ABC 1921	UK			Yes
ABC 1936	UK			Yes
ACONF	UK			Yes
Actifcare (400)	Netherlands	Yes		
AddNeuroMed	UK	Yes		
ADGEN	Finland	Yes		
ADNI-1	US	Yes		
ADNI-2	US	Yes		
ADNI-GO	US	Yes		
AgeCoDe - German Study on Aging, Cognition and Dementia in Primary	Germany	Yes		
Ageing in Leganes (Envejecer en Leganes)	Spain			
AGES	Iceland	Invitation sent		
Airwave	UK			Yes
ALFA STUDY (Alzheimer's and Family)	Spain			
ALPHA: Ageing in Liverpool Project- Health Aspects. (Part of CFAS)	UK			
ALSPAC - other family members COCO90s (children of children)	UK			
ALSPAC Children of the 90s	UK			
Alzheimer Disease & Frontotemporal Dementia Mutation Database (AD &	Belgium			
AMI Cohort - Integrated multidisciplinary approach	France			
AMPLE	UK			Yes
AMSTEL Amsterdam Study of the Elderly	Netherlands			
Amsterdam Dementia Cohort (4K)	Netherlands	Yes		
ANCOG The Antwerp Cognition Study	Belgium			
Antwerp cohort	Belgium	Yes		
Anxiety and cognitive decline in dementia	Norway	Invitation sent		
ARS	Italy		Yes	
ASL Arterial Spin Labeling	Switserland			
ARWIBO	Italy	Yes		
Athens Cohort	Greece	Yes		
AUH	Denmark		Yes	
BAS Belgian Ageing Studies Project	Belgium			
BASEI and BASEII Berlin Ageing Studies	Germany			
BCN-SANTPAU	Spain	Yes		
BCS58 1958 Birth Cohort	UK			
BCS70 1970 Birth cohort	UK			
BDR	UK			Yes
Berlin Study for Outcome-Related Health Care Evaluation of People with	Germany			
Betula Prospective Cohort Study	Sweden			
BIFAP (7.6M)	Spain			
BIOFINDER Study (The Swedish)	Sweden	Invitation sent		
Born in Bradford	UK			
BRHS British Regional Heart Study	UK			
Bremen cohort	Germany	Invitation sent		
Brussels cohort	Belgium	Invitation sent		
BWHHS British Women's Heart and Health Study	UK			
CAIDE - Cardiovascular risk factors in ageing and dementia	Sweden/Finland	Yes		
CAM_CAN	UK			Yes
Cambridge Brain Bank (CBB)	UK			
Cambridge Center for Ageing and Neuroscience (Cam-CAN)	UK			
Cambridge City over-75s Cohort (CC75C)	UK			

CAMD CODR-Coalition Against Major Diseases Critical Path Institute Or	Multi-country + US			
CamPaIGN	UK			Yes
CaPS The Caerphilly Prospective Study	UK			Yes
Caregiver QoL	Brazil	Invitation sent		
CBAS Czech Brain Aging Study	Czech Republic			
Center for Integrated Molecular Brain Imaging (Cimbi) database	Denmark			
CFAS 1	UK			Yes
CFAS 11	UK			Yes
CFAS Wales Cohort - Maintaining function and well being in later life	UK			
Chariot	UK			Yes
ClinAD	France			
CogLaus - Lausanne Cohort	France	Yes		
Cognition, Brain, and Aging (COBRA) Project	Sweden			
Coimbra cohort	Portugal			
CONOR Cohort of Norway	Norway			
Conselice Study of Brain Ageing	Italy			
CONSTANCES - CONSulTANts des CES-Centres d?examens de santé	France			
COSM Cohort of Swedish Men	Sweden			
Copenhagen cohort	Denmark	Invitation sent		
Costs MCI primary care	Germany	Invitation sent		
CPRD (5M)	UK			
Cygnus Care Cohort (500)	UK	Yes		Yes
DCN - Dementia Competence Network	Germany	Yes		
DCR - Dementia Case Register	UK	Yes		
Deep & frequent phenotype	UK	Invitation sent		yes
DELCODE	Germany	Invitation sent		
DelpHi-MV	Germany	Invitation sent		
DEMDATA	Czech Republic & Austria	Invitation sent		
Dementia in Swedish Twins (HARMONY)	Sweden			
Dementia Platform UK	UK			
DeNoPa - De Novo Parkinsion	Germany	Yes		
DESCRIPA	Netherlands	Yes		
DESCRIPA 1	11 countries			
DESCRIPA population cohort	Netherlands	Yes		
Dementia Study	Germany			
DFP	UK			Yes
DiMi - Diagnostic molecular imaging	Germany	Yes		
DISCAPARAGON Zaragoza province	Spain			
Doetinchem Cohort Study	Netherlands			
Donepezil	France	Yes		
Dutch End Of Life in Dementia (DEOLD) study	Netherlands			
Dynamic Analyses to Optimise Ageing (DYNOPTA)	Australia			
DZNE Longitudinal Cognitive Impairment	Germany			
EADC prodromal	Netherlands	Yes		
EDAR	Netherlands	Yes		
EGCUT	Estonia		Yes	
ELES project (Longitudinal Study Aging in Spain)				
English Longitudinal Study of Ageing (ELSA)	UK			Yes
Enhancing Care in Alzheimer's Disease Study (ECAD)	UK			
EPIC Norfolk	UK			Yes
Epidemiological study in the elderly German population (ESTHER)	Germany			
EpiChron Cohort	Spain			
EpiHealth cohort	Sweden			
ERGO-onderzoek Cohort - Rotterdam study. 3 cohorts	Netherlands			
European Male Ageing Study	8 countries			
FAD & DIAN	UK			Yes
FINE. Finland, Italy, the Netherlands, Elderly	Finland, Italy, Netherlands			
FINGER - The Finnish Geriatric Intervention Study	Finland	Yes		
Finnish twin studies	Finland			
FINRISK	Finland	Invitation sent		
French National Alzheimer Databank (BNA)	France			

French National Study on ADR	France	Invitation sent		
Freiburg cohort	Germany	Invitation sent		
Fundacio ACE, Barcelona Alzheimer treatment and research center	Spain			
GAP - Proyecto Gipuzkoa Alzheimer	Spain	Yes		
GAZEL. GAZ and Electricité	France			
Generation R study	Netherlands			
GENFI	UK			Yes
GePaRD	Germany		Yes	
GERAS	Europe	Invitation sent		
German National Cohort (The) - NAKO	Germany			
GOAL Good ageing in Lahti Region	Finland			
Gospel Oak	UK			
Gothenburg MCI	Sweden	Yes		
Gothenburg Population Studies (10K)	Sweden			
GS:SFHS	UK			Yes
GS=SFHS Scottish Family Health Study	UK			
H2000 Cohort Health 2000	Finland			
H70 cohorts	Sweden	Yes		
H85 cohorts	Sweden			
HAS. The Hertfordshire Ageing Study and other cohorts	UK			
HELIAD Hellenic Longitudinal Investigation of Aging and Diet	Greece	Yes		
Helmholtz Alliance for Mental Health in an Ageing Society	Germany			
HSCIC (56M?)	UK			
HSD	Italy		Yes	
HSE. The Health Survey for England	UK			
Human prion diseases: molecular characteristics	Germany			
HUNT studies Helseundersøkelsen i Nord-Trøndelag. 3 adult cohorts, 2	Norway	Invitation sent		
ICICLE-PD	UK			Yes
ICTUS	Europe	Invitation sent		
IDIBAPS	Spain	Yes		
ILSE Inter-disciplinary longitudinal study of adult development	Germany			
IMAP+ - Multimodality Imaging of Early Stage Alzheimer's Disease	France	Yes		
IMASIS	Spain		Yes	
InCHIANTI study	Italy			
Interdisciplinary Longitudinal Study of Adult Development and Aging (I	Germany			
IPCI	Netherlands		Yes	
IPCI Primary Care (2M)	Netherlands			
Italian Longitudinal Study on Aging (ILSA)	Italy			
Italian Project on the Epidemiology of Alzheimer Disease (IPREA) study	Italy			
KORA-Age	Germany			
Krakow cohort	Poland	Invitation sent		
Kungsholmen Project (The)	Sweden			
Lambeth DataNet	UK		Yes	
LASA Longitudinal Ageing study Amsterdam ; Lasa 1 & 2	Netherlands			
LBC 1936	UK			Yes
LeARN In vivo molecular diagnostics in Alzheimer's. WP4 (300)	Netherlands	Yes		
Leipzig cohort	Germany	Invitation sent		
Leuven 1	Belgium	Yes		
Lewy-Pro	UK			Yes
Life Study. 2014 birth cohort	UK			
LifeLines Cohort Study	Netherlands			
LISA register (10M)	Sweden			
Lisbon cohort	Portugal	Invitation sent		
Ljubljana cohort	Slovenia	Invitation sent		
L-MCI - Kuopio Longitudinal MCI Study	Finland	Yes		
Lolipop (London life Sciences Population Study)	UK			
Longitudinal Aging Study Amsterdam	Netherlands			
Lothian Birth Cohorts (LBC 1921 and 1936)	UK			
LSYPE Longitudinal Study of Young People in England	UK			
LUCAS Longitudinal Urban Cohort Ageing Study	Germany			
LULEA Northern Swedish Cohort	Sweden			
Lundby study	Sweden			

Luxembourg Cohort	Luxembourg			
Luxembourg National Cohort	Luxembourg			
MAAS	UK		Yes	
MAAS Maastricht Aging Study	Netherlands			
Maastricht cohort	Netherlands			
Madrid cohort	Spain	Invitation sent		
Memora	France	Invitation sent		
MCI-GO	Norway	Yes		
MCS Millenium Birth cohort	UK			
Melton Mowbray	UK			
Memento	France	Yes		
Memo_Vie	Luxembourg			
Men in Gothenburg: cohorts 1-5. Women from 2003	Sweden			
Metropolit	Denmark			
Midspan family studies :Main (M)and Tiree (T), Collaborative Study ©	UK			
Midspan studies: Renfrew and Paisley (G1) and Family Study (G2)	UK			
Milan Cohort	Italy	Yes		
Million Women	UK			Yes
MIND Cohort - Minho Integrative Database on Ageing	Portugal			
Monzino 80-plus Study	Italy			
MRC NSHD	UK			Yes
MRC-CFAS	UK	Yes		
Multicare1. Patterns of multimorbidity in primary health care	Germany			
MultiDomain Alzheimer Preventive Trial (MAPT)	France			
MYHAT	USA	Invitation sent		
Nat. patient registers (5.6M)	Denmark			
National Alzheimer's Coordination Center (NACC)	United States			
National Institute for Mental Health Research (NIMHR)	Australia			
NCLS Netherlands Cohort Study	Netherlands			
NEDICES Neurological Disorders of Central Spain	Spain			
NEDICES II	Spain			
NEDISA Neurological Disorders in Salamanca	Spain			
NEST-DD	UK	Yes		
Neuropsychiatric symptoms aMCI Spain	Spain	Invitation sent		
Newcastle 85+ Study	UK			
NFBC66, NFBC86 N. Finland birth cohorts	Finland			
NICOLA Northern Ireland Cohort for Longitudinal Study of Ageing	UK			
NILS Northern Ireland longitudinal study and NIMS	UK			
NIMROD	UK			Yes
NLSAA Nottingham Longitudinal Study of Activity and Ageing	UK			
NSHD National Survey of Health and Development	UK			
OPCD Discovery	UK			Yes
Origins of Variance in the Oldest-Old (OCTO-TWIN)	Sweden			
Oslo Cohort	Norway	Yes		
PaMIR	UK			Yes
PAQUID	France	Invitation sent		
PATH through life	Australia			
PEDIANET	Italy		Yes	
Penagrande	Spain			
Perceived stigma early stage dementia	USA	Invitation sent		
Perugia Cohort	Italy	Yes		
PHARMACOG	Italy	Yes		
PHARMO	Netherlands		Yes	
PICNICS	UK			Yes
Plan de Soin et d'Aide dans la maladie d'Alzheimer (PLASA)	France			
PLM (Paris-North, Lille and Montpellier) study	France			
PolSenior	Poland			
Pre-AI Study Prediction of Alzheimer's Disease	France	Yes		
PREVENT	UK			Yes
Prospective Population Study of Women in Goteborg (PPSW)	Sweden	Yes		
PRIME Caregiver substudy	Australia	Invitation sent		
PROTECT	UK			Yes

PSI - Pralsnoer Institute	Netherlands	Yes		
REAL.FR study	France			
RECALL-HNR - Heinz Nixdorf Recall Study	Germany	Yes		
ReDeGi - Registro de Demencias de Girona (6K)	Spain			
ReGAI Project - Rete Geriatrica Alzheimer	Italy	Yes		
Resource Utilization MCI	USA	Invitation sent		
Reykjavik Heart Study & AGES	Iceland			
Rhineland study (the)	Germany			
Right Time Place Care Study	EU	Invitation sent		
Rotterdam Study	Netherlands			
SABRE	UK			Yes
SAIL (3M)	UK			
Santander cohort	Spain	Invitation sent		
SATS Swedish Alzheimer Treatment Study	Sweden	Invitation sent		
SATSA Swedish Adoption/Twin Study of Aging - also HARMONY	Sweden			
Scottish Dementia Clinical Research Network - SDCRN	UK			
Scottish longitudinal study	UK			
SCTS	UK		Yes	
Scinawa cohort	Poland	Invitation sent		
SDR	UK		Yes	
SENECA Survey in Europe on Nutrition and the Elderly: a Concerned Ac	Multiple			
SHARE	Multi-country, EU+			
SHIP (5.7M)	UK			
SHIP Study of Health in Pomerania: two cohorts. (SHIP, SHIP-TREND)	Germany			
SIDIAP	Spain		Yes	
SLSR	UK		Yes	
SNAC-K - The Swedish National study on Aging and Care in Kungsholm	Sweden	Yes		
Speedwell	UK			
Stockholm Birth cohort	Sweden			
Strasbourg cohort	France	Invitation sent		
SveDem - Swedish Dementia Registry	Sweden			
SWEOLD Swedish Panel Study of Living Conditions of the Oldest Old	Sweden			
Swiss National Cohort	Switzerland			
SWS Southampton Women's study	UK			
Sydney Memory and Ageing Study-MAS	Australia			
TEMPO	France			
THIN	UK		Yes	
TILDA - The Irish Longitudinal Study on Ageing	Ireland			
Tours cohort	France	Invitation sent		
TRACK-HD	UK			Yes
TREND - Tübinger evaluation of Risk factors for Early detection of Neur	Germany			
UbCos Multigenerational Uppsala Birth cohort	Sweden			
UK Bio bank	UK			
UK CRIS (3M)	UK			
UK Women's cohort	UK			
UKB	UK			Yes
UK-CRIS	UK		Yes	
Understanding Society cohort	UK			
UpCos Uppsala birth cohortmulti-generational	Sweden			
Uppsala AD-NHP (Nursing Home Placement) study	Sweden	Invitation sent		
Uppsala Longitudinal Study of Adult Men (ULSAM)	Sweden	Invitation sent		
Vantaa 85+	Finland	Invitation sent		
VEGA health care reg. (1.6M)	Sweden			
Vitality 90+	Finland			
VP-EDAD The Vallecas Project - Early detection of Alzheimer's Disease	Spain			
Warsaw cohort	Poland	Invitation sent		
WHICAP-Study of aging and dementia among elderly in Washington He	United States			
Whitehall II The stress and health study	UK			Yes
Zagreb cohort	Kroatia	Invitation sent		
ZARADEMP Zaragoza demential depression project cohort	Spain	Invitation sent		
Zutphen Elderly Study	Netherlands			